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5Abstract
Essential hypertension, a major public health concern, is associated with increased 
cardiovascular mortality. High dietary salt (NaCl) is the best studied and most important 
predisposing risk factor. Excessive salt intake leads to renal and cardiac dysfunction by blood 
pressure dependent and independent mechanisms. Sedentary lifestyle and overnutrition 
contribute to the increasing prevalence of hypertension, obesity, atherogenic dyslipidemia 
and dysglycemia. These constitute a pathophysiological state referred to as metabolic 
syndrome, and are associated with cardiovascular mortality.
Elevated circulating urate is a common finding in these disorders, and it has been 
suggested to be an independent risk factor to cardiovascular diseases. Being the terminal 
metabolite of human purine metabolism, urate levels reflect the balance between intake, 
production and excretion. While dysregulation of urate excretion has been reported in 
association with cardiovascular disorders, present studies aimed to clarify the role of the 
urate producing enzyme, xanthine oxidoreductase (XOR), i.e. the gene product xanthine 
dehydrogenase (XDH) and its post-translationally formed isoform xanthine oxidase (XO), 
in cardiovascular diseases.
XOR converts hypoxanthine and xanthine, derived from ATP and other purine 
nucleotides, to urate. In the rat liver, but not in the kidney, uricase converts urate to 
allantoin. While urate is an endogenous antioxidant, XO can produce reactive oxygen 
species (ROS), which are involved in cell signalling and associated with organ dysfunction 
if the production rate is high. Among other factors, low oxygen levels upregulate XOR, and 
if prolonged, also increase the conversion of XDH to XO.
Cross-transplantation studies between hypertension-prone and -resistant rat strains 
have revealed a major role for the kidney in salt-sensitive hypertension. Salt overload and 
resulting hypertension induce hemodynamic changes and energy demand which in turn 
may lead to renal hypoxia. 
In present studies hypertension-prone rat strains were found to have higher renal XOR 
activity than salt-resistant strains. Furthermore, NaCl intake upregulated dose-dependently 
renal XOR isoforms only in hypertension-prone rats. Salt-sensitive and -resistant rats were 
then kept on ‘low’ and ‘high’ NaCl diets for different periods of time, with or without the 
specific XOR inhibitor allopurinol, to clarify whether renal XOR induction precedes or 
follows the development of hypertension. Renal XOR induction appeared concomitantly 
with blood pressure elevation. While allopurinol did not significantly alleviate hypertension, 
6it prevented left-ventricular and renal hypertrophy indicating a possible role for XOR in 
salt-induced target organ damage.
Nitric oxide synthases (NOS) catalyze the main pathways for the production of nitric 
oxide (NO). NO is an endothelium-derived relaxing factor with pleiotropic paracrine 
effects and is able to modify renal sodium excretion. ROS produced by XO can scavenge 
NO. XOR resembles bacterial nitrate reductases and may be able to recycle nitrate to NO. 
Therefore the impact of a paucity or surplus of NO on XOR regulation was investigated. 
NOS inhibition by L-NAME aggravated salt-induced hypertension and induced renal 
XOR, whereas NO prodrug, isosorbide-5-mononitrate, alleviated salt-induced hypertension 
without modulating renal XOR.
XOR expression and activity were further studied using Zucker fa/fa strain, which 
is a prediabetic rodent model of metabolic syndrome. These rats developed substantial 
obesity and modest hypertension. In contrast to lean controls, hepatic and renal XOR 
activities were upregulated. XOR activities were modified by diet and downregulated by 
the angiotensin II receptor blocking agent, valsartan.
Cyclosporine (CsA) is a fungal cyclic undecapeptide and one of the first-line 
immunosuppressive drugs used in the management of organ transplantation. Renal 
vasoconstriction and malignant hypertension and other renal side effects ensue high CsA 
doses. As a result, CsA nephrotoxicity limits its use and is aggravated by dietary NaCl. 
Substantial CsA-induced renal XO upregulation was found in salt-sensitive rats kept on 
high NaCl diet, indicating a possible role for this ROS producing isoform in CsA-induced 
nephrotoxicity.
In conclusion, the present studies demonstrated upregulation of XOR in obese and 
salt-sensitive rat strains. Furthermore, renal XOR was induced by dietary salt. NOS and 
angiotensin II participate in XOR regulation. XO upregulation followed drug-induced 
nephrotoxicity. Renal hypoxia, common to these models, is one of the plausible XOR 
inducing factors. Although XOR inhibition did not alleviate hypertension, present 
experimental data indicate that XOR plays a role in in the pathology of salt-induced cardiac 
and renal damage. 
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Main abbreviations
11HSD2 11 ß-hydroxysteroid-dehydrogenase (EC 1.1.1.146)
ACE Angiotensin convertase (EC 3.4.15.1)
ALDH Aldehyde dehydrogenase (EC 1.2.1.3
Ang II Angiotensin II
ARB Angiotensin receptor blocker
ANOVA Analysis of variance
AO Aldehyde oxidase (EC 1.2.3.1)
AP Allopurinol
AT1 Angiotensin receptor type 1
AT2 Angiotensin receptor type 2
ATP Adenosine triphosphate
BP Blood pressure
BH4 5,6,7,8-Tetrahydrobiopterin 
CsA Cyclosporine
Dahl SS/Jr Dahl salt sensitive rat strain
Dahl SR/Jr Dahl salt resistant rat strain
DOCA Deoxy-corticosterone acetate
DPI Diphenylene iodonium
FAD Flavin adenine dinucleotide
G6PDH Glucose-6-phosphate dehydrogenase (EC 1.1.1.49)
GSH Glutathione, reduced form
GSSG Glutathione, oxidized form
IL-1- -interleukin 1
I/R Ischemia-reperfusion
IS-5-MN Isosorbide-5-mononitrate
L-NAME N-nitro-L-arginine methyl ester
LDH Lactate dehydrogenase (EC 1.1.1.27)
LVH Left ventricular hypertrophy
MAP Mean arterial pressure (also Mitogen-activated protein kinase)
Moco Molybdenum cofactor
mRNA Messenger ribonucleic acid
NAD(P)+ Nicotine adenine dinucleotide (phosphate), oxidized form
NAD(P)H Nicotine adenine dinucleotide (phosphate), reduced form
NFAT Nuclear factor of activated T-cells
NOS Nitric oxide synthase (L-Arginine, NADPH: oxygen oxido  
 reductase, EC 1.14.13.39)
NYHA New York Heart Association
QTL Quantitative trait locus
RA(A)S Renin angiotensin (aldosterone) system
ROS Reactive oxygen species
SBP Systolic blood pressure
SHR Spontaneously hypertensive rat
SOD Superoxide dismutase (EC 1.15.1.1)
TAL Thick ascending loop
TNF- Tumor necrosis factor 
XDH Xanthine dehydrogenase (EC 1.17.1.4)
XO Xanthine oxidase (EC 1.1.3.22)
XOR Xanthine oxidoreductase
WKY Wistar Kyoto
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1 Introduction
Arterial blood pressure is regulated by cardiac output and peripheral resistance. Sustained 
increase in arterial pressure is defined as hypertension and is usually the result of increased 
resistance in resistance vessels. In up to 95% of subjects with hypertension, the underlying 
cause for high blood pressure is not known (Staessen et al., 2003). The remaining five 
percent of cases, in which the underlying cause is known, are referred to as having secondary 
hypertension. Despite the progress in prevention and treatment, the prevalence of essential 
hypertension remains high, more than 25% of adult population worldwide (Kearney et al., 
2005).
Cut-off values for blood pressure levels in the diagnosis of hypertension are related to 
occurrence of other cardiovascular risk factors, prognostic information, and to the capacity 
of health care systems. Generally a blood pressure exceeding 140/90 mmHg (systolic/
diastolic) is considered high (Arguedas et al., 2009).
Essential hypertension is an established risk factor for atherosclerosis and stroke, which 
are considered among the leading causes of death. In addition to genetic predisposition, 
diet is an important multifactorial determinant of blood pressure (Miller et al., 1999). 
Epidemiological studies have indicated that high salt (NaCl) intake is an independent risk 
factor for cardiovascular and renal disease (Boero et al., 2002). Obesity, sedentary life-style 
and a low intake of vegetables are also independent risk factors for hypertension. These 
factors further contribute to the aggregation of hypertension with abdominal obesity, 
dyslipidemia and insulin resistance that together constitute metabolic syndrome.
Metabolic syndrome is now recognized as one of the key factors resulting in the 
increased prevalence of diabetes and cardiovascular disease worldwide. The prevalence of 
diabetes in EU region is currently 6.8% of total population and is expected to reach 7.8% 
in 2025. Similar trend is also predicted in developing countries (The International Diabetes 
Foundation, Diabetes atlas, 2008). In developed countries type 2 diabetes accounts for 85 
to 95% of all diabetes cases and in developing countries the percentage is even higher.
Systolic blood pressure (SBP) response to dietary NaCl is not homogenous. Salt-sensitive 
individuals have an exaggerated SBP response to changes in NaCl intake. In hypertension 
population, the percentage of salt-sensitive individuals has been estimated to be as high 
as 70% (Weinberger, 1996). Experimental studies on kidney transplantation between salt-
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resistant and salt-sensitive rats have demonstrated the crucial role of the kidney in salt-
sensitivity (Rettig and Grisk, 2005).
Association of high serum urate levels with the development of essential hypertension 
has been known for decades, but the underlying mechanisms are still not fully understood. 
Urate is a biochemical marker, which has even been suggested to be an independent risk 
factor for essential hypertension, metabolic syndrome and cardiovascular diseases (Strasak 
et al., 2008a and 2008b). Circulating urate levels reflect the balance between its elimination 
and production, and the availability of endogenous and dietary precursors.
In humans, urate (uric acid) is the end-product of purine metabolism because of the 
genetic silencing of the enzyme uricase (Oda et al., 2002). In the rat, hepatic uricase 
converts circulating urate to the more water soluble allantoin. Increased levels of urate have 
been shown to be nephrotoxic in rats (Mazzali et al., 2002). The nephrotoxic properties of 
urate have been proposed to contribute to the development of salt-sensitive hypertension 
(Watanabe et al., 2002).
Urate is produced by the enzyme xanthine oxidoreductase (XOR) from xanthine and 
hypoxanthine, both of which are degradation products of ATP and other purine nucleotides. 
Xanthine dehydrogenase (XDH, EC 1.1.1.204) is the translated protein. Post-translational 
modifications can transform XDH into xanthine oxidase (XO, EC 1.1.3.22), which yields 
electrons to oxygen instead of NAD+, resulting in increased ROS production (Hille and 
Nishino, 1995).
While XOR is one of the main sources of reactive oxygen species (ROS), XOR is also 
an enzyme, which produces one of the most powerful endogenous antioxidative molecules, 
urate. ROS are by-products of oxygen metabolism and are important cell signalling 
molecules.
Increased ROS production, by XOR and other enzymes, has been shown to associated 
with hypertension in animal models and in severe forms of human hypertension. ROS 
production, particularly H2O2, has been shown to participate in the regulation of renal 
sodium excretion and endothelial function. ROS may thus contribute to salt-sensitive 
hypertension (Taylor et al., 2005). ROS may also react with NO and regulate NO 
availability. NO is a potent endothelium-derived vasodilatating factor and has multiple 
roles including regulation of renal sodium excretion (Lahera et al. 1991) and regulation of 
oxygen consumption at cellular level (Victor et al. 2007). Recently, XOR has been reported 
to contribute to recycling of NO metabolite nitrate back to NO (Jansson et al., 2008). 
The physiological and pathophysiological significance of this pathway with respect to 
cardiovascular homeostasis has not been fully evaluated yet. ROS, reactive nitrogen species 
and urate have been shown to play a role in innate immune function (reviewed by Vorbach 
et al., 2003; Bianchi, 2007).
The aim of the present studies was to characterize the possible role of XOR in salt-
sensitive rat models of hypertension and metabolic syndrome using specific hypertension-
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prone and obesity-prone rat strains and their genetically close control strains. Possible 
association of XOR with salt-sensitivity was studied in rats on different levels of salt 
intake for different periods of time. Effects of XOR inhibition on the development of salt-
induced hypertension were also studied to clarify whether regulation of renal XOR activity 
had any causal role. Because XOR has potential interrelationships with NO homeostasis, 
one of the aims was to clarify whether NO paucity or excess would regulate XOR activity. 
Cyclosporine (CsA) belongs to first-line drugs for immunomediated diseases and it is 
particularly useful to prevent rejection after organ transplantation. However, CsA use is 
limited by its nephrotoxicity, which is associated with renal vasoconstriction and functional 
changes resulting in malignant hypertension. In addition, CsA toxicity has been reported 
to be aggravated by dietary NaCl (Pere et al., 1998).
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2 Review of the literature
2.1 long-term regulation of blood pressure 
Several physiological mechanisms are involved in the long-term regulation of blood 
pressure. The complex array includes regulation by endocrine and paracrine hormonal 
mechanisms, sympathetic nerve system, central nervous system, cardiac output, peripheral 
resistance and renal mechanisms.
The kidney regulates long-term blood pressure by adjusting sodium, chloride and 
volume homeostasis with high precision. The relationship between chronic intake level 
of sodium chloride, and resulting blood pressure response, has been defined by Guyton 
and co-workers as an S-shaped curve, or alternatively, the chronic pressure-natriuresis 
curve (Guyton et al., 1972), as depicted in Figure 1. Mechanisms, which regulate long-term 
balance of blood pressure and volume homeostasis, modify the chronic pressure-natriuresis 
curve. The curve indicates that the increased NaCl excretion in salt-sensitive subjects is 
achieved at increased blood pressure levels. All types of hypertension are associated with a 
‘right shift’ in the pressure-natriuresis curve.
The renin-angiotensin system (RAS) or renin-angiotensin-aldosterone system (RAAS), 
are the most important long-term blood pressure regulating mechanisms. Aspartyl protease 
renin (EC 3.4.99.19) is released from the kidney and acts on the circulating hepatic protein 
angiotensinogen converting it to a decapeptide, angiotensin I. This peptide is then further 
converted in the vascular bed to the octapeptide, angiotensin II (Ang II) by the membrane 
bound zinc metallopeptidase, angiotensin convertase (ACE, EC 3.4.15.1) (reviewed by 
Le et al., 2008). The effects of Ang II in blood pressure regulation are mediated by AT1 
receptors. The second receptor class, AT2, has opposing effects compared with AT1. Ang II 
is a vasoconstrictor and participates in volume regulation by liberating mineralocorticoid, 
aldosterone. ACE also cleaves other peptides. It inactivates bradykinin, which is a strongly 
vasodilatating peptide and opposes the effects of Ang II. The importance of these classical 
pathways (Figure 2) became evident after the discovery of ACE inhibitors, which are still 
widely used antihypertensive drugs. The pathway provided also other important targets for 
antihypertensive treatments, including AT1 receptor blockers. Recently, renin inhibitors 
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have been introduced as a novel class of antihypertensive drugs (reviewed recently by 
Jensen et al., 2008). Further cleavage of Ang II produces hepta- (Ang III and Ang 1–7) and 
hexapeptides (Ang IV), which also exert biological activity. Ang II is the most potent of 
these peptides. While so called classical RAS pathways involve circulating components, 
there is growing interest in intracellular RAS, which involves alternative Ang II and Ang 1–7 
generating systems, such as catepsin and chymase, and possibly also nuclear receptors. 
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Figure 1. Schematic overview on arterial pressure in relation to NaCl intake (i.e. NaCl 
excretion). To excrete all sodium at a given intake level, salt-sensitive subjects (dashed red 
curve) require higher arterial pressure levels than salt-resitant (black curve). In salt-sensitive 
individuals the slope of the curve is decreased. Salt-sensitivity is determined by a variety of 
genetic and endocrine factors (see text). While natriuretic hormones and antihypertensive 
drugs cause left-shift in the curve, the activation of RAAS increases circulating aldosterone 
level and, sodium reabsorption, and results in a shift to the right. Rodent models indicate that 
salt-sensitivity can be induced by urate exposure, reactive oxygen species or by inhibition of 
NO production (see text). Oxygen availability in the kidney is also one of the factors which 
can modify the pressure-natriuresis curve (Modified from Guyton et al. (1972). 
Growing interest on RAS began already in 1898, when Finnish physiologist 
Robert Tigerstedt discovered a renal blood pressure increasing protein, renin, and the 
field is still expanding (Fyhrquist and Saijonmaa, 2008). The kidney is unique in 
having all components of RAS within one tissue. In addition to the liver, the kidney is 
able to synthesize angiotensinogen. Renal Ang II concentrations are much higher than 
can be anticipated from levels delivered by circulation. Furthermore, Ang II levels are 
higher in specific parts of the kidney. Consequently locally generated Ang II in the 
kidney may be more important than circulating Ang II (reviewed by Kobori et al. 
2007). It is also possible that Ang II receptor blockers exert their effects by 
upregulating Ang1-7, rather than by inhibiting Ang II effects directly (reviewed by 
Lubel et al. 2008). 
Figure 1. Schematic overview on arterial pressure in relation to NaCl intake (i.e. NaCl excretion). 
To excrete all sodium at a given intake level, salt-sensitive subjects (red line) require higher arterial 
pressure levels than salt-resitant (black line). In salt-sensitive individuals the slope of the curve is 
decreased. Salt-sensitivity is determin d by a variety of genetic and end crine factors (see text). 
While natriuretic hormones and antihypertensive drugs cause left-shift in the curve, the activation 
of RAAS increases circulating aldosterone level and, sodium reabsorption, and results in a shift to 
the right. Rodent models indicate that salt-sensitivity can be induced by urate exposure, reactive 
oxygen species or by inhibition of NO production (see text). Oxygen availability in the kidney is 
also one of the factors which can modify the pressure-natriuresis curve. Modified from Guyton et 
al. (1972).
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Growing interest on RAS began already in 1898, when Finnish physiologist Robert 
Tigerstedt discovered a renal blood pressure increasing protein, renin, and the field 
is still expanding (Fyhrquist and Saijonmaa, 2008). The kidney is unique in having all 
components of RAS within one tissue. In addition to the liver, the kidney is able to 
synthesize angiotensinogen. Renal Ang II concentrations are much higher than can be 
anticipated from levels delivered by circulation. Furthermore, Ang II levels are higher in 
specific parts of the kidney. Consequently locally generated Ang II in the kidney may be 
more important than circulating Ang II (reviewed by Kobori et al. 2007). It is also possible 
that Ang II receptor blockers exert their effects by upregulating Ang 1–7, rather than by 
inhibiting Ang II effects directly (reviewed by Lubel et al. 2008).
Recently uric acid has been reported to increase dose-dependently Ang II production 
in vascular smooth cell cultures, linking urate to RAS and cardiovascular effects (Corry et 
al., 2008).
Figure 2. Classical pathways of the renin-angiotensin system, and the kallikrein-kinin system are 
depicted. Recently alternative pathways have gained much interest. In these Ang II is converted by 
ACE2 to Ang 1–7 and to Ang 1–9 , which exert their effects through MAS receptors.Collated from 
different sources cited in the text.
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2.2 the role of the kidney in  
2.2 the development of hypertension
Abnormal kidney function has a pivotal role in the predisposition to NaCl induced 
hypertension. In order to study the role of the kidney in the development of hypertension, 
renal cross-transplantation experiments were carried out in the 1980s by Rettig and Grisk using 
salt-resistant and hypertension-prone salt-sensitive rat strains (Grisk et al., 2002; Rettig and 
Grisk, 2005). Kidney transplants derived from normotensive salt-resistant rats were shown to 
result in sustained decrease the systolic blood pressure of an adult salt-sensitive recipient and 
abolish the predisposition to hypertension in young animals (Morgan et al., 1990; Roman, 
1986). These observations, based on studies on the Dahl salt-sensitive (Dahl SS/Jr) and salt-
resistant (Dahl SR/Jr) rat, established the crucial importance of the kidney in the pathogenesis 
of hypertension. In the spontaneously hypertensive rat (SHR) and its normotensive control, 
the Wistar-Kyoto rat (WKY), renal homografts were rejected, but similar experiments with F1 
hybrids were successful and confirmed the previous results on Dahl strains.
The renal cross-transplantation experiments were carried out with rats kept on a ‘low’ 
dietary NaCl level. Repeating the experiments with rats kept on a ‘high’ dietary NaCl diet 
indicated that in addition to renal mechanisms also extrarenal mechanisms play a role, 
since the hypertension-prone, salt-sensitive Dahl SS/Jr rat with a kidney homograft from 
salt-resistant rat still developed hypertension (Morgan et al., 1990).
The kidney has a major role in the development of hypertension and at the same time 
is one of the target organs of the harmful effects of hypertension As such, a vicious cycle is 
formed and further emphasizes renal involvement in the development of hypertension.
Reduced renal blood flow is one of the characteristic findings in hypertension (Welch 
et al., 2001). Generally, in all tissues, lower blood flow means decreased oxygen delivery. 
In the case of the kidney, lower blood flow could be partly compensated by lower energy 
expenditure, since the workload for reabsorption of solutes is decreased. Tubular ischemia 
has been recognized to participate in the pathological renal changes resulting in the 
development of salt-sensitive hypertension (Johnson et al., 2002).
 
2.3 salt-sensitivity
Pressure response to dietary NaCl varies with genetic background. Individuals who have 
high blood pressure responses to an acute change in salt-intake have been referred to as 
salt-sensitive. The division is categorical. In human studies a change of 10% or more in 
mean arterial blood pressure (MAP) has been used to define salt-sensitivity. A <5% change 
in MAP defines salt-resistance. While salt-sensitivity refers to an acute response, dietary 
NaCl has delayed effects on blood pressure, which are associated with the development of 
hypertension (Van Vliet et al., 2008).
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The prevalence of salt-sensitivity among hypertensive patients has been estimated to be 
high, approximately 50% (Poch et al., 2001). Compelling evidence has accrued that high 
dietary NaCl intake markedly contributes to the development of arterial hypertension. 
There is also a substantial amount of evidence for a universal recommendation to restrict 
the intake of NaCl to 5 grams per day in order to prevent or decrease the prevalence of 
hypertension and its harmful consequences (Sacks et al., 2001). 
Sustained increase of arterial blood pressure results from insufficient renal NaCl 
excretion in relation to dietary load. Increases in systolic blood pressure are accompanied 
with increased NaCl excretion, which tends to correct the blood pressure change (Guyton 
et al., 1972). 
The renin-angiotensin system is closely associated with salt-sensitivity. In addition, 
several other factors modify salt-sensitivity including nitric oxide, the kallikrein-kinin system 
and eicosanoids. In clinical studies, salt restriction resulted in compensatory activation of 
RAAS, which tends to oppose changes in blood pressure. If RAAS is blocked, e.g. by ACE 
inhibitors, blood pressure becomes more dependent on salt intake (He and MacGregor, 
2003). Other studies have shown that infusion of angiotensin II to the salt-resistant dogs 
results in a profound blood pressure response to salt-loading (Hall et al., 1980).
In experimental animals with or without genetic predisposition to hypertension, salt 
overload suppresses renin release into circulation from juxtamedullary cells and subsequent 
RAAS response. Salt-sensitivity can also be seen as an inability to suppress RAAS in response 
to increased NaCl intake.
In spite of blunted RAAS response to NaCl load, Ang II receptor blockers attenuate salt-
induced experimental hypertension effectively. These phenomena have led to a hypothesis 
involving local renin-angiotensin system (for review, see Fyhrquist and Saijonmaa, 2008). 
Salt-loading inactivates RAAS and consequently, salt-induced sustained increase in blood 
pressure has been referred to as low renin hypertension. In contrast, the local renin 
angiotensin system is activated by NaCl and results in an increase of cardiac AT1 receptors. 
Furthermore, the local renin angiotensin system is involved in stimulation of growth and 
may participate in hypertension associated cardiac hypertrophy (Liang et al., 2007).
2.3.1 Sodium and chloride
The human body has adapted to ancient low sodium diets and tends to keep sodium 
and chloride. As such, the homeostasis is challenged by the high salt intake, provided by 
modern diets. Most NaCl in human diets is derived from industrially processed food. It is 
considered practically impossible to compose an otherwise balanced diet, which would not 
provide adequate amounts of sodium chloride.
Only few studies have attempted to clarify which one of the ions, sodium or chloride 
is more important in relation to harmful cardiovascular effects of dietary NaCl. In 
several experimental studies sodium loading with other anions except chloride has 
22
failed to increase blood pressure (Boegehold and Kotchen, 1989 and 1991). While 
in hypertension-prone, Dahl SS/Jr rats, NaCl is most potent, varying the anion 
component does not completely abolish the increases in blood pressure (Roman and 
Kaldunski, 1991).
Ang II stimulates the release of mineralocorticoid aldosterone from the adrenal gland 
resulting in an increased sodium reuptake. Cortisol also has mineralocorticoid activity, 
which become significant in high concentrations. Salt-sensitive individuals show increased 
cortisol/cortisone ratios. Cortisol is inactivated mainly by renal 11-hydroxysteroid 
dehydrogenase-2 (11HSD2), an enzyme, which is easily inhibited by liquorice saponin, 
glycyrrhizin, resulting in markedly increased cortisol levels and blood pressure (Quinkler 
and Stewart, 2003). Experimentally similar condition can be generated in rats by the 
administration of deoxycortisone acetate with NaCl (DOCA-NaCl). In this hypertension 
model, dietary sodium overload without chloride (as acetate etc.) does not increase blood 
pressure (Ziomber et al., 2008).
2.3.2 Interrelationships with other dietary ions
Observational and intervention studies have consistently indicated that vegetarian diets 
are associated with beneficial effects on blood pressure, even when intake of NaCl is not 
different from omnivores (Berkow and Barnard, 2005). In the DASH trial (The Dietary 
Approaches to Stop Hypertension) marked positive cardiovascular effects of a diet 
comprising of increased amounts of fruits, whole grains, nuts, vegetables, fish, poultry and 
reduced amounts of red meats, sweets and sugared beverages has been reported (Sacks et 
al., 2001). Akita et al. (2003) found that the DASH diet decreases the slopes of steady-state 
pressure-natriuresis curves. This finding indicates that salt-sensitivity is decreased. At low 
Na+ -intake levels, the effects of the DASH diet vanished.
While the exact mechanisms have not been determined, the positive effects of vegetarian 
diets have been attributed to the low levels of sodium and chloride, to high contents of 
potassium, calcium and magnesium, to high levels of fibre, polyphenols, to the content of 
polyunsaturated fatty acids and to low energy density. One of the recent hypotheses is that 
the beneficial effects of these type of diets are related to the high NO 3 
- levels of vegetables 
(Webb et al., 2008b), as is further discussed in Section 2.6 Nitric oxide.
The effect of dietary NaCl in the development of hypertension and subsequent 
cardiovascular disorders is modified by other mineral ions present in the diet. In rodent 
models supplementation of potassium and magnesium has attenuated development of 
hypertension (Mervaala et al., 1992). Mg2+ is an important cofactor in reactions requiring 
ATP and probably acts as a mild calcium antagonist by promoting vascular relaxation. 
Mg-deficiency promotes inflammation in rodent studies. Although experimental and 
epidemiological studies indicate a role for Mg2+ in hypertension, data from clinical studies 
have been less convincing (Bo and Pisu, 2008).
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Increased intake of calcium lowers blood pressure in rodent models of hypertension 
(Hatton et al., 1994). Dietary NaCl increases calcium loss in the urine (Mervaala et al. 
1994b). Data from intervention studies have been controversial, although some of the 
clinical studies show significant positive effects (Sabbagh and Vatanparast, 2009).
 
To summarize preceding Sections 2.1 to 2.3: Several overlapping mechanisms are involved in 
long-term regulation of blood pressure. RAAS is one of the most important systems involved in 
chronic blood pressure regulation. Experimental cross-transplantation studies indicate that salt-
sensitivity and hypertension ’go with the kidney’, highlighting the importance of the kidney 
in the development of hypertension. Hypertension is always associated with a ‘right-shift’ of 
pressure natriuresis curve and salt-sensitivity with a decrease of its slope. While sodium intake 
in human nutrition mostly translates to the intake of NaCl, sensitivity to sodium and chloride 
may vary among subjects. Beneficial effects of vegan diets have been attributed to low NaCl 
levels and high levels of other ions, particularly potassium. Also the high nitrate levels found in 
vegetables has been suggested to mediate these effects, an issue, which remains to be clarified.
2.4 salt-induced target organ effects
2.4.1 Hypertrophy
High blood pressure is associated with left ventricular hypertrophy and renal enlargement 
in addition to impaired endothelial function. The left ventricular hypertrophy may exist 
even independently of increased blood pressure in response to increased intake of NaCl. 
Salt-induced increase in renal mass has been described both in the presence and absence of 
increased systolic blood pressure (Radin et al., 2008). Several environmental and genetic 
risk factors have emerged. At the moment it is not known, which genetically determined 
structural or biochemical disorders explain the development of essential hypertension.
Increasing salt intake results in salt-sensitive rats in marked hypertension and left 
ventricular and renal enlargement within weeks. The genetically related salt-resistant rats 
develop these harmful, NaCl-induced effects to a much lesser extent (McCormick et al., 
1989; Mervaala et al., 1994a and 1994b).
Increased renal mass, due to renal hypertrophy or hyperplasia, can occur in response 
to electrolyte overload (Mervaala et al., 1994a and 1994b). It also occurs in several different 
physiological and pathophysiological conditions, which include increased blood pressure, 
metabolic syndrome, diabetes mellitus and compensatory growth. One of the most 
important factors contributing to hypertension induced renal enlargement is Ang II. In the 
kidney effects of Ang II are mediated by the AT1 receptor (Wolf and Wenzel, 2004). Both 
uric acid and Ang II have been reported to stimulate vascular smooth cell proliferation in 
culture and, furthermore, urate has been reported to upregulate intracellular levels of Ang 
II (Corry et al., 2008).
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2.4.2 Renal hypoxia
All tissues depend on adequate oxygen supply. The two kidneys represent approximately 
1% of body weight, but receive 20% of the resting cardiac output. Renal outer medulla 
and cortex are, however, remarkably susceptible to hypoxia because of effective oxygen 
shunting in the kidneys (Schurek et al., 1990). In spite of an abundant blood supply, the 
kidney is sensitive to changes in O2 availability. This sensitivity enables the kidney to 
regulate O2 transport, e.g. by controlling the blood erythrocyte count via erythropoietin 
secretion. At the same time, the possibility of hypoxia is increased.
The medullary thick ascending limb has high Na+/K+-ATPase activity and oxygen 
demand. NaCl load results in renal enlargement. It can be hypothetized that NaCl-induced 
renal hypertrophy may increase the diffusion distances for oxygen and result in lowered 
oxygen availability in the most susceptible areas. Hemodynamic changes in the kidney, 
e.g., increased vascular resistance, during the development of hypertension may also alter 
oxygen tension in the kidney (Matavelli et al., 2007).
Tubular ischemia has been recognized to contribute to the development of salt-
sensitive hypertension (Johnson et al., 2002). Decreased number of renal glomeruli, as well 
as structural difference in the glomeruli, may partially explain changes in renal function 
in prehypertensive SHR (Skov et al., 1994). The excretion of concentrated urine requires 
energy and high amounts of oxygen (Brezis and Rosen, 1995). 
The ability to produce concentrated urine is challenged by increased sodium intake. 
In a normal physiological state renal medulla is at the brink of hypoxia (Schurek et al., 
1990). High NaCl intake may result in increased energy demand and subsequent reduction 
in oxygen availability. Development of hypertension results in pathologic hemodynamic 
changes, which may contribute to the development of areas of relative hypoxia in the 
kidney. Hemoglobin levels in SHRs are higher than in the WKY rats (Welch et al., 2001), 
which lends support to the hypothesis of renal hypoxia. High hemoglobin levels may also 
increase peripheral resistance and contribute to hypertension.
Decreased renal NAD+/NADH ratios have been found in several rodent models of 
hypertension including salt-induced hypertension (Orbetzova et al., 1976). Isolated tubular 
cells from SHR, during the development of hypertension are reported to have 15% to 25% 
higher oxygen consumption and slightly lower ATP levels than cells from WKY, even when 
hypertension was treated with drugs (Brazy et al., 1989). The SHR kidney may therefore be 
more susceptible to hypoxia than kidney of WKY rat during the excretion of excess sodium.
Renal ability to produce concentrated urine is also based on high osmolyte concentration 
in renal medulla (Eckstein and Grünewald, 1996). In order to increase urine osmolarity to 
meet the challenges associated with high NaCl intake, it is anticipated that higher osmolyte 
levels are needed, the generation of which also requires energy. Renal circulation has 
effective shunting, which may contribute to the stability of osmolar gradients, but renders 
the kidney susceptible to decreased oxygen availability. 
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Decreased capillary density have been shown to contribute to the development of 
hypertension in the SHR model, since stimulation of angiogenesis by subjecting young 
SHRs to hypoxic conditions has been shown not only to increase capillary density, but also 
prevent development of hypertension (Vilar et al., 2008) in rats kept on a standard diet.
There is experimental evidence that decreased oxygen tension is found in association 
with diabetes (Palm, 2006). Recent studies indicate that renal hypoxia upregulates the 
renin-angiotensin system, which in turn causes vasoconstriction of efferent arterioles and 
increases ROS production (Nangaku et al., 2007) which likely occurs at the expense of O2 
available for energy production. As hypoxia upregulates XOR activity, tissue XOR levels 
may reflect oxygen availability (Terada et al., 1997).
Wang and co-authors (2008) recently found that hypoxia increases production of 
IL-6, a proinflammatory cytokine, in cultures of lung microvascular endothelial cells 
concomitantly with XDH/XO upregulation. It was also found that IL-6 antibodies nearly 
reversed XOR upregulation (Wang et al., 2008). Furthermore, it was also shown in the 
same study that IL-6 is upregulated by increasing NaCl intake in Dahl SS rats, but not in 
the salt-resistant Dahl SR rats.
Chronically increased blood pressure can contribute to renal damage by several 
mechanisms leading to inflammation and infiltration of immunocompetent cells. In animal 
models renovascular hypertension, association of hypertension with inflammation has been 
a constant finding (Rodriguez-Iturbe et al., 2002a, Rodriguez-Iturbe et al., 2002b).
2.4.3 Cyclosporine (CsA) nephrotoxicity
CsA is a common immunosuppressive agent used in organ transplantation. CsA binds 
to cyclophilin and the complex inhibits calcineurin, a proteinphosphatase involved in 
dephosphorylation of members of the nuclear factors of T-cells (NFAT), which then 
translocate into the nucleus (Beals et al., 1997). NFATs induce synthesis of interleukins. 
Inhibition of calcineurin by CsA inhibits gene expression of activated T-cells via NFAT 
pathway (Matsuda et al., 2000a). In addition to calcineurin inhibition, there is evidence that 
CsA exert its immunosuppressive effects also by blocking JNK and p38 signaling pathways 
during T-cell activation (Matsuda et al., 2000b). Interestingly p38 has been reported also to 
phosphorylate XDH and XO (Kayyali et al., 2001). Recent reports indicate that calcineurin 
is involved in the development of cardiac hypertrophy and, furthermore, CsA has been 
shown to reverse cardiac hypertrophy in rats (Hongzhuan et al., 2008).
 Nephrotoxicity limits CsA use in organ transplantation. Therapeutic CsA doses can 
result in malignant hypertension by impairing renal function. Development of CsA-
induced renal damage proceeds with several mechanism leading e.g. to hyperuricemia as 
renal function becomes compromised. On the other hand hyperuricaemia has been shown 
to exacerbate CsA-induced nephropathy (Mazzali et al., 2001b). These phenomena relate to 
levels of circulating urate and renal elimination mechanisms and provide one possible vicious 
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cycle, which is associated with CsA toxicity. In the context of XOR, it is however interesting 
to note that CsA administration results in renal hypoxia by marked Ang II induced renal 
vasoconstriction. Furthermore, CsA toxicity is exacerbated by increased dietary intake of 
NaCl (Pere et al., 1998). Allopurinol, a specific XOR inhibitor, has been added into some 
of the cold storage solutions used to preserve kidney transplants (Baatard et al., 1993).
In theory, CsA induced vasoconstriction and other factors resulting in hypoxia can lead 
to XOR induction, generation of ROS and NO metabolites, add to the urate load and finally 
contribute to harmful renal effects of CsA. Hypoxic adaptation involves upregulation of 
angiogenesis, glycolysis and erythropoiesis. In many tissues decreasing oxygen consumption 
by induction of the pentose phosphate shunt is one of the adaptive mechanisms. The 
hypoxia inducible factor (HIF-1) is one of the regulating factors involved. Inhibition of 
HIF-1 by CsA has been reported in cell cultures of glioma cells, and has been suggested to 
contribute to CsA toxicity (D'Angelo et al., 2003). CsA inhibits calcineurin, which in turn 
regulates HIF-1 expression (Liu et al., 2007). Induction of XOR by hypoxia is however 
not mediated by HIF-1 (Linder et al., 2003).
 
To summarize the Section 2.4: While the kidney has a crucial role in the development of 
hypertension, it is also one of the target-organs for harmful effects of sustained increases in 
SBP. In a normal physiological state, renal medulla is at the brink of hypoxia. High NaCl 
intake may result in compromised oxygen availability. NaCl induced renal hypertrophy may 
increase diffusion distances for oxygen. Decreased capillary density may contribute to the 
development of hypertension in hypertension prone rats. Nephrotoxic effects of CsA are in 
part mediated by renal vasoconstriction. CsA nephrotocity is aggravated by dietary NaCl.
2.5 oxidative stress and hypertension
Vascular endothelium plays a crucial role in hemodynamic homeostasis. Endothelial 
cells synthesize NO, which is a vasodilator and contributes to endothelial health. ROS, 
in particular superoxide, have been suggested to react with NO, decreasing its availability 
and thus contributing to endothelial dysfunction. This phenomenon has been associated 
also with clinical hypertension (Landmesser and Drexler, 2007a). An increased endothelial 
production of superoxide has been found in several experimental models of hypertension 
including Dahl SS rats (Zicha et al., 2001) and the SHR model (Schnackenberg et al., 
1998). In contrast, vascular production of superoxide was not associated with increased 
blood pressure induced by 5-day infusion of adrenaline (Kawazoe et al., 2000; Laursen 
et al., 1997).
Potential sources of reactive oxygen species in the circulation include XO, 
cyclooxygenases, NAD(P)H oxidase, also NADH oxidase activity of XDH, uncoupled 
NO synthases, mitochondrial respiratory enzymes and lipoxygenases (Szasz et al., 2007).
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XO, which is a post-translationally modified form of XDH, may pass electrons to oxygen 
in favour over NAD+ and generate ROS. XO has been identified as one of the major H2O2 
and O 2 
-  generating enzymes in the endothelium along with NAD(P)H oxidase, and the 
mitochondrial electron transport chain (Iuchi et al., 2003). Once formed, O 2 
-  gives rise to 
other ROS molecules, such as H2O2, by the action of superoxide dismutase (SOD).
Both XDH and XO (to a lesser extent) exhibit NADH oxidase activity with simultaneous 
ROS production. This activity is inhibited by diphenylene iodonium (DPI), but it is not 
inhibited by oxopurinol or allopurinol (Zhang et al., 1998a).
NAD(P)H oxidase and reactive oxygen species have also been shown to associated with 
dexamethasone induced hypertension in mice (Hu et al., 2006). Angiotensin II infusion 
increases ROS production, a process which can be prevented by apocynin.
Studies on NAD(P)H oxidase have to a great extent relied on two putative inhibitors, 
apocynin and DPI. While the former has been shown to be an antioxidant with no inhibiting 
activity, the inhibiting activity of the latter requires dimerization by myeloperoxidase, an 
enzyme, which is not present e.g. in vascular endothelium. Currently there are no specific 
inhibitors of NAD(P)H oxidase. NAD(P)H oxidase is a complex consisting of several 
protein components, which hampers interpretation of mRNA based studies. Consequently, 
some of the studies on NAD(P)H oxidases should be interpreted cautiously (Heumuller 
et al., 2008).
While NADPH oxidase is a membrane-bound protein and produces superoxide anions 
in the extracellular space, XOR is cytosolic and is therefore associated with intracellular redox 
homeostasis. As a cytosolic enzyme XO is released under pathophysiological conditions 
into circulation and is able to bind to the extracellular matrix of cells via glycosaminoglycan 
residues. Cell-bound XO retains its ability to produce superoxide anions (Adachi et al., 
1993; Houston et al., 1999).
ROS have a well-established role in the regulation of sodium retention in the kidney 
(Taylor et al., 2005), which is mediated by ROS induced degradation of NO. NO has a 
major role in controlling renal hemodynamics and sodium excretion (Zou and Cowley, 
1999). Furthermore, O 2 
-  is able to directly induce sodium reabsorption (Ortiz et al., 2002). 
The major demand for oxygen in the kidney is related to the active transport of sodium 
ions. Hypertonic infusion in the medullary thick ascending limb has been reported to 
increase oxidative stress (Mori and Cowley, 2004).
ROS are potentially harmful and scavenged by specific enzymes or endogenous and 
exogenous redox active molecules. Inhibition of uricase by oxonic acid to the extent which 
produces only modest increase in urate levels, not high enough to produce microcrystals, 
results in the development of salt-sensitivity and hypertension in salt-resistant rats (Mazzali 
et al., 2001a). These findings point towards that urate, although being an antioxidant, 
contributes to development of hypertension rather than alleviates it.
There is an ongoing discussion on the role of oxidative stress in clinical hypertension. It 
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has not yet been clarified whether increased oxidative stress is a pathological consequence of 
hypertension, a predecessor of it, or whether is involved in the development of it. Most of 
epidemiological studies (involving up to 250 000 subjects) do not lend support to the idea 
that supplementation with common antioxidative vitamins would prevent cardiovascular 
diseases (Howes, 2006).
More recent studies seem to indicate that oxidative stress contributes to hypoxia in the 
kidney and compromise renal function (Welch, 2006). Treatment of hypertension with 
antihypertensive drugs has been reported to decrease ROS production (Landmesser et al., 
2007b).
 
To summarize: Large epidemiological studies on association of cardiovascular diseases with 
dietary antioxidative agents have been negative. ROS are indispensable physiological signal 
transducers, which may become harmful only if their production rate exceeds endogenous 
scavenger capacity of metabolizing enzymes and redox active compounds. Association of 
ROS with hypertension is well-established in experimental models. It is not known whether 
increased ROS production precedes hypertension.
2.6 nitric oxide (no)
Nitric oxide is an established vasodilator and has a wide range of biological functions, 
which link reduced availability of NO with pathogenesis of hypertension, atherosclerosis 
and diabetes. NO plays a crucial role in sodium retention (Zou and Cowley, 1999).
The role of vascular endothelium in vasoregulation became apparent only after 
identification of the endothelial relaxing factor, which is synthesized from L-arginine by 
NO synthases (NOS) mainly in the endothelium (Moncada and Higgs, 2006). In mammals 
three different NOS enzymes exist: constitutive, inducible and neuronal NOS.
NO has been shown to play a crucial role in renal medullary oxygenation (Brezis 
and Rosen, 1995). As reviewed recently by Palm and co-workers (2009), NO competes 
with oxygen for the binding site in cytochrome oxidases and inhibit mitochondrial 
oxygen expenditure. This occurs, when levels of oxygen are low in comparison to 
NO, i.e. in hypoxia. NO is able to increase the efficiency of electrolyte transport per 
consumed oxygen molecule in the renal tubulus. In Sprague-Dawley rats increasing 
dietary salt intake upregulates endothelial, inducible and neural NOS in renal medulla, 
indicating the importance of NOS in adaptation to dietary salt load (Mattson and 
Higgins, 1996).
Chronic, unselective inhibition of NOS by N-nitro-L-arginine methyl ester (L-
NAME) was first described as a model of hypertension by Oliveira-Ribeiro et al. in 1992. L-
NAME was shown to produce a marked renal vasoconstriction and hypoperfusion, which 
could partially be reversed by L-arginine infusion, but not by D-arginine (Ribeiro et al., 
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1992). While renal cortical blood flow was reported to remain unaltered, renal medullary 
blood flow was markedly decreased (Nakanishi et al., 1995). L-NAME has been shown 
to decrease NO production in mice from 70% to 90% (Wickman et al., 2003). We have 
previously shown that chronic NOS inhibition downregulates renal glutathione synthesis 
(Levonen et al., 2000), which may render the kidney more vulnerable to harmful effects of 
increased ROS production. Increased levels of the endogenous NOS inhibitor, asymmetric 
dimethyl arginine have been associated with acute coronary events in epidemiological 
studies (Valkonen et al., 2001).
Chronic NOS inhibition results in sodium and water retention leading to hypertension, 
not only in genetically hypertension-prone experimental animals, but also in normotensive, 
salt-resistant rats (Mattson et al., 1994). Low dose L-NAME treatment, not sufficient to 
increase blood pressure, has been reported to transform salt-resistant dogs to salt-sensitive 
(Salazar et al., 1993).
Generation of peroxynitrite from reaction of NO with ROS can inactivate NO, and it has 
been suggested as one of the mechanisms explaining why the inhibition of ROS producing 
enzyme XO can lead to the improvement of endothelial function (George et al., 2006). 
Sickle cell disease, which is caused by a mutation in -globin, results in polymerization 
of the mutated hemoglobin and subsequent episodes of ischemia/reperfusion in tissues 
e.g. in the liver. An increased level of circulating XO, which originates from the liver, has 
been reported in sickle cell disease. Circulating XO binds avidly to cells of the vascular 
lumen. Markedly increased XO-dependent vascular oxidative stress has been observed 
to contribute to vascular dysfunction, which is a hallmark of the disease. Clinically, the 
disease is not associated with hypertension. Mice models of sickle cell disease do not show 
increased blood pressure, but they are fivefold more sensitive to blood pressure increasing 
effects of the NOS inhibitor L-NAME than controls (Aslan et al., 2001).
 
To summarize Section 2.6: NO is a potent endothelium derived vasodilator, which has  
several other roles including regulation of renal oxygenation. NO is produced by NOS.  
NOS inhibition results in malignant hypertension. Low doses, not enough to produce 
increased SBP, can render salt-resistant animals to salt-sensitive.
2.7 urate
2.7.1 Urate as an antioxidant
XOR catalyzes the rate limiting step of purine metabolism producing urate. Recent 
prospective large epidemiological studies suggest a role for urate as an independent risk 
factor for cardiovascular diseases. Strasak et al. (2008b) studied more than 28 000 elderly 
Australian women and reported serum uric acid as an independent predictor of all major 
forms of cardiac deaths. In an even larger study, more than 83 000 Australian men, had 
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similar outcome (Strasak et al., 2008a). The association of high serum urate levels with 
the development of essential hypertension has been known for decades (Cannon et 
al., 1966, Prebis et al., 1981). The underlying biochemical mechanisms have still not 
been fully elucidated. A significant association of plasma urate and XOR activity with 
mean arterial blood pressure has been observed in clinical studies among normotensive 
individuals (Newaz et al., 1996).
In most mammals circulating urate levels are kept low by hepatic microsomal uricase, 
which degrades urate to the more water-soluble allantoin. In the rat, renal uricase is not 
expressed and the kidney produces at least 7% of total excreted urate (Chin et al., 1980). 
Uricase is silenced in humans and other primates as a consequence of two independent 
mutations (Oda et al., 2002). Urate excretion is relatively low in humans, and consequently, 
its levels in the circulation are high, approximately 50 times higher than in the rat. In humans, 
urate filtered through glomerulus is reabsorbed effectively by the URAT1 transporter while 
only 5–10% is excreted (Anzai et al., 2007). Several agents including nonsteroidal anti-
inflammatory drugs and losartan, an Ang II receptor antagonist and antihypertensive drug, 
exhibit uricosuric effects by inhibiting the URAT1 transporter (Enomoto et al., 2002). The 
kidney can regulate changes in circulating urate levels, which may result from increases 
in urate production induced by dietary purine intake or from an increase in endogenous 
production (Rieselbach et al., 1964).
Clinical studies on lowering urate with the uricosuric agent, probenicid, did not result 
in an improvement of endothelial function (George et al., 2006). Systemic administration 
of uric acid to healthy men, in order to temporarily increase circulating urate, did not 
exert any effect on hemodynamic variables or NO dependent endothelial function 
(Waring et al., 2004). However, in other experimental settings contradictory results were 
obtained. Intravenous urate infusions in rodents have been reported to result in endothelial 
dysfunction (Khosla et al., 2005). In human studies urate infusion improved endothelial 
function in subjects with type 1 diabetes and in smokers (Waring et al., 2001).
In experimental studies, increasing circulating urate levels in rats by the uricase 
inhibitor, oxonic acid, have been shown to result in renal arteriolopathy and hypertension 
(Mazzali et al., 2001a; Mazzali et al., 2002; Sanchez-Lozada et al., 2002; Johnson et al., 
2003). The increased urate levels were reported to induce salt-sensitivity in rats (Mazzali 
et al., 2001a) with stimulation of the renin angiotensin system. Based on these studies 
uric acid has been proposed to participate in the development of human salt-sensitivity 
(Watanabe et al., 2002).
Urate is one of the most potent water-soluble antioxidants, even more effective than 
ascorbate (Waring et al., 2001). In addition, urate is able to chelate transition metals, such 
as iron, thus protecting its environment from Fenton reactions, which generate ROS. 
Urate has been shown to protect ROS inactivating superoxide dismutase enzymes SOD1 
and SOD3 from ROS-induced loss of activity (Hink et al., 2002). 
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While various treatments with antioxidative compounds have been effective in alleviating 
hypertension in rodent models (Tian et al., 2005), clinical studies relating to treatment of 
hypertension with antioxidants have not been encouraging. The finding that urate rather 
worsens rather than alleviates hypertension in rodent models does not support the view 
of urate having a role as an antioxidant preventing increased blood pressure through the 
scavenging ROS.
In humans urate shows a circadian rhythm in close association with NO (Kanabrocki 
et al., 2000). Urate scavenges peroxynitrite (OONO-), an oxidative compound derived 
from the reaction between NO and O 2 
-, which is also capable of reacting with proteins 
and other cellular constituents (Squadrito et al., 2000). Urate has been reported to exert 
neuroprotective effects against inflammation in rodent models of multiple sclerosis by 
scavenging peroxynitrite (Hooper et al., 1998, Spitsin et al., 2000). Urate can also react 
directly with NO, producing nitrated urate. In this form, it may decompose back to NO 
and act as NO reservoir or vehicle (Suzuki, 2007). The finding points towards the possibility 
that locally generated urate might be able to modify the effects of NO.
2.7.2 Urate modifies immune function
Immunization with a protein can lead to tolerance unless an adjuvant, such as aluminum 
oxide, is co-administered and resulting in a stimulated immune response. Bacterial wall 
components also act as adjuvants. Dead cells from the body itself are immunogenic, 
indicating that some endogenous components may also act as adjuvants. Several molecules, 
including monosodium urate, purinergic metabolites, heat shock proteins and nuclear 
proteins, have been postulated to stimulate innate immunological response and together 
form a damage-associated molecular pattern (Bianchi, 2007).
Tissue damage increases local degradation of nucleotides, for example ATP, DNA 
and RNA. Subsequently dying cells liberate xanthine and hypoxanthine, which are then 
converted to urate by XOR. The liberated uric acid acts as a danger signal and endogenous 
adjuvant (Shi et al., 2003). Urate crystals have been shown to activate dendritic cells, which 
upon activation orchestrate the immune system (Shi et al., 2006). In humans circulating 
urate levels are high and increased local production may result in the precipitation of 
microcrystals. Precipitation of urate and consequent activation of the immune system is 
the mechanism responsible for the clinical manifestation of gout. High urate concentration 
in humans is therefore a sensitive trigger for the immune system to act in the event of tissue 
damage, and, as an endogenous adjuvant. In solution uric acid or urate is also a modulator 
of the immune system (Shi et al., 2006). 
Local production of urate by XOR may initiate an immune response. In a recent 
double-blind clinical trial, the XOR inhibitor allopurinol reduced the rise of inflammatory 
markers after acute ischemic stroke, most notably the proinflammatory surface adhesion 
molecule ICAM-1 (Muir et al., 2008). Experimentally ICAM-1 has been shown to be 
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important in hypertension related end-organ damage (Mervaala et al., 1999). Rodent 
models of hypertension have been shown to involve recruitment of macrophages and 
other immunocompetent cells into the kidney. Immunosuppression has been reported to 
alleviate hypertension in Dahl salt-sensitive rats (Tian et al., 2007). However, the role of 
urate has not been clarified in these experimental settings.
 
To summarize Section 2.7: Urate is produced by XOR in a reaction, which is rate limiting in 
purine metabolism. As an antioxidant it may protect NO against ROS. Urate may also protect 
NO from degradation by forming a complex with it. In rats, moderately increased urate levels 
result in hypertension and salt-sensitivity. Urate acts also as an adjuvant and may contribute to 
dietary NaCl and hypertension-induced target organ inflammation. Increased urate levels may 
have nephrotoxic properties.
2.8 xanthine oxidoreductase (xor)
As early as 1902, an enzyme fraction present in whole milk was found to decolorize 
methylene blue in the presence of formaldehyde by Schardinger (1902). Twenty years after 
this discovery, the same enzyme fraction was found to produce urate (Morgan et al., 1922). 
Later urate production was shown to belong to the terminal rate-limiting steps in human 
purine catabolism from the purine nucleotide degradation products hypoxanthine and 
xanthine by the same ‘Schardinger enzyme’ or xanthine oxidoreductase. These pathways 
are depicted schematically in Figure 3. In humans, urate is a terminal metabolite, unlike in 
the rat liver where urate is further oxidized to allantoin.
XOR exists in two interconvertible isoforms, xanthine dehydrogenase (XDH, EC 
1.2.1.37) and xanthine oxidase (XO, EC 1.1.3.22). XO is a post-translationally modified 
form of the initial gene product XDH. In the rat, the gene coding XDH protein is located 
on chromosome 6 (at 6q13) and the human sequence on chromosome 2 (at 2p23.1, Rytkönen 
et al., 1995).
In the reaction with hypoxathine or xanthine, the XO isoform transfers electrons 
to molecular oxygen generating reactive oxygen species, such as superoxide anion and 
hydrogen peroxide. XDH in turn transfers the electrons, generated from production 
of urate from hypoxanthine and xanthine, to NAD+, which is subsequently reduced to 
NADH (Fridovich, 1970, Harris and Massey, 1997; Hille and Nishino, 1995).
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Figure 3. Schematic presentation of purine metabolism. Reactions involving XOR activity are 
highlighted with red colour. Purines are expensive in terms of the number of ATPs used in their 
synthesis. Blue colour refers to salvage pathways, which are energetically important as purine synt-
hesis consumes high amount of ATP molecules. IMP, inosine monophosphate; S-AMP, succinyl 
monophosphate; XMP, xanthine monophosphate.
 
As is depicted in the three-dimensional presentation in Figure 4, XOR is a nonglycosylated 
metalloflavoprotein which contains two identical 145 kDa subunits. Each subunit has 
one molybdopteridin site, one FAD site and two Fe-S centers. The XOR sequence shows 
remarkable similarity with other molybdoenzymes, and it has partially overlapping substrate 
specificity with aldehyde oxidase (AO) (Garattini et al., 2008).
Mutation of two amino acids in the amino acid cluster that determines the conformation 
around the FAD prosthetic group, favours the XO conformation and increases superoxide: 
hydrogen peroxide ratio from 1:3 to 6:1 (Asai et al., 2007).
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Twenty years after this discovery, the same enzyme fraction was found to produce 
urate (Morgan et al., 1922). Later urate production was shown to belong to the 
terminal rate-limiting steps in human purine catabolism from the purine nucleotide 
degradation products hypoxanthine and xanthine by the same Ô Schardinger enzymeÕ  
or xanthine oxidoreductase. These pathways are depicted schematically in Figure 3. 
In humans, urate is a terminal metabolite, unlike in the rat liver where urate is further 
oxidized to allantoin. 
XOR exists in two interconvertible isoforms, xanthine dehydrogenase (XDH, EC 
1.2.1.37) and xanthine oxidase (XO, EC 1.1.3.22). XO is a post-translationally 
modified form of the initial gene product XDH. In the rat, the gene coding XDH 
protein is located on chromosome 6 (at 6q13) and the human sequence on 
chromosome 2 (at 2p23.1, Rytkš nen et al., 1995). 
In the reaction with hypoxathine or xanthine, the XO isoform transfers electrons 
to molecular oxygen generating reactive oxygen species, such as superoxide anion 
and hydrogen peroxide. XDH in turn transfers the electrons, generated from 
production of urate from hypoxanthine and xanthine, to NAD+, which is subsequently 
reduced to NADH (Fridovich, 1970, Harris and Massey, 1997; Hille and Nishino, 
1995). 
 
Figure 3. Schematic presentation of purine metabolism. Reactions involving XOR activity are 
highlighted with red colour. Purines are expensive in terms of the number of ATPs used in 
their synthesis. Blue colour refers to salvage pathways, which are energetically important as 
purine synthesis consumes high amount of ATP molecules. 
As is depicted in the three-dimensional presentation in Figure 4, XOR is a 
nonglycosylated metalloflavoprotein which contains two identical 145 kDa subunits. 
Each subunit has one molybdopteridin site, one FAD site and two Fe-S centers. The 
XOR sequence shows remarkable similarity with other molybdoenzymes, and it has 
partially overlapping substrate specificity with aldehyde oxidase (AO) (Garattini et 
al., 2008). 
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Figure 4. Three dimensional model of bovine xanthine oxidase showing -helixes and -pleated 
sheets. The enzyme is a 300 kDa homodimer. FAD site is visible upper left. Data from Enroth  
et al. (2000) depicted using Molecular Visualization Applications by Moreland et al.(2005).
2.8.1 Distribution
XOR has been detected in all mammalian cells as well as vertebrates, invertebrates, higher 
plants, green algae, fungi and bacteria. It is an integral part of the purine catabolism in all 
cells. In mammals highest activities are found in the intestine, liver, mammary gland and 
bile ducts.
As an enzyme capable to produce ROS, reactive nitrogen species and the endogenous 
adjuvant, urate, XOR is related to innate immunity and, along with another antimicrobial 
enzyme lysozyme, is expressed in capillary endothelial surfaces (Spiekermann et al., 2003), 
in mammary gland epithelia and other epithelial surfaces, epithelial secretions, milk and 
phagocytes (Vorbach et al., 2003).
In circulation, the XO isoform prevails. The highest levels of circulating levels of XO 
have been found in rats. Circulating antibodies against XOR exist in healthy individuals. 
The antibodies do not inhibit the enzyme, but may have a role in accelerating the turnover 
of the ROS producing enzyme (Benboubetra et al., 1997).
Khan et al. (2004) found that deficiency of neuronal NOS (NOS1 isoform), but not 
endothelial NOS (NOS3), induced XOR in murine cardiac myocytes. Increased ROS 
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Mutation of two amino acids in the amino acid cluster that determines the 
conformation around the FAD prosthetic group, favours the XO conformation and 
increases superoxide: hydrogen peroxide ratio from 1:3 to 6:1 (Asai et al., 2007). 
 
Figure 4. Three dimensional model of bovine xanthine oxidase showing α-helixes and β-
pleated sheets. The enzyme is a 300 kDa homodimer. FAD site is visible  upper left. Data 
from Enroth et al. (2000) depicted using Molecular Visualization Applications by Moreland 
et al.(2005). 
2.8.1 Distribution 
XOR has been detected in all mammalian cells as well as vertebrates, invertebrates, 
higher plants, green algae, fungi and bacteria. It is an integral part of the purine 
catabolism in all cells. In ammals highest activities are found in the intestine, liver, 
mammary gla d and bile ducts. 
As an enzyme capable to produce ROS, re tive itrogen species and the 
endogenous adjuvant, urate, XOR is related to innate immunity and, along with 
another antimicrobial enzyme lysozyme, is expressed in capillary endothelial surfaces 
(Spiekermann et al., 2003), in mammary gland epithelia and other epithelial surfaces, 
epithelial secretions, milk and phagocytes (Vorbach et al., 2003). 
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production by XOR was found with depression of myocardial excitation-contraction 
coupling, which was reversed by XOR inhibition with allopurinol. Neuronal NOS and 
XOR were found in the same immunoprecipitate and also in the same sarcolemmal fraction 
obtained by sucrose gradient chromatography. These results indicate that XOR and NOS1 
are located in close proximity to each other in cardiac sarcolemma (Khan et al., 2004).
XOR is an abundant protein in milk, from where it was first isolated. In mice and 
cattle XOR represents 1–2% of total soluble protein of lactating glands. In milk XOR 
is present predominantly in XO isoform and does not contain molybdenum. XO is a 
structural element participating in the enveloping of fat droplets in milk, where it also 
has an antimicrobial role. In lipid globules of milk, XOR is associated with butyrophilin 
suggesting a role in the formation and secretion of milk lipid (Murphy and Vance, 1999).
2.8.2 Regulation of XOR activity and expression
XOR is subject to post-translational modifications. For a summary of modifying factors 
and inductors, see Table 1.
Hypoxia is one of the best known factors that regulate XOR (Lanzillo et al., 1996, Terada 
et al., 1997). XOR activity is rapidly changed by hypoxia (within 4 hours), indicating that 
protein synthesis is not initially required (Linder et al., 2003). However, at a later stage 
(24 hours or more) protein synthesis also becomes involved. The p38 kinase, or the ‘stress-
induced kinase’, is involved in events resulting in phosphorylation of XDH/XO and is 
regulated by hypoxia (Kayyali et al., 2001; Kinugawa et al., 2005). Tissue XOR activity may 
increase in areas of hypoxia as XOR activity is suppressed in normoxia. 
Proinflammatory mediators, such as lipopolysaccharide and cytokines, have been 
reported to increase endothelial XO expression (Brandes et al., 1999). XOR expression is 
induced by inflammatory cytokines, such as TNF-, IL-1 and IFN-, suggesting a role 
for XOR in inflammatory processes (Page et al., 1998). IL-3 also contributes to XDH to 
XO conversion (Friedl et al., 1989). In human monocyte cultures, XOR inhibition by 
allopurinol decreases ICAM-1  expression (Mizuno et al., 2004). Along with I/R process and 
subsequent ROS production by XO (described in the previous Chapter), these phenomena 
have an association with defence against bacterial invasion, as such an occurrence could 
eventually obstruct circulation.
Sulfuration of Moco (see Section 2.8.3) is essential for human XOR activity. Deficiency 
of the Moco sulfurase enzyme results in XOR and aldehyde oxidase deficiency (Ichida et 
al., 2001).
XOR is an abundant protein in milk. XOR expression in the mammary gland is tightly 
regulated by secretory activity (McManaman et al., 2002). Lactogenic hormones, prolactin 
and cortisol, increase XOR expression and activity by up to 500% as demonstrated by 
incubating mammary epithelial cells with these hormones. This effect was inhibited by 
genistein, a tyrosine kinase inhibitor and by MAP kinase pathway inhibitor. (McManaman 
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Table 1. Factors, which regulate and modify XOR activity and/or expression
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et al., 2000). Mice, made deficient of XOR by gene knockout, do not live beyond 6 weeks. 
XOR +/- mice have normal appearance, but are not able to lactate normally, and their pups 
die (Vorbach et al., 2002).
2.8.3 Molybdenum cofactor (Moco)
The oxidation of xanthine and hypoxanthine takes place at the Mo center of the enzyme. 
Concomitant reduction reactions are catalyzed by the two FAD centers of the molecule. 
Molybdenum cofactor is an essential for all molybdenum enzymes (Nason et al., 1971). 
Known mammalian molybdoenzymes include in addition to XOR, aldehyde oxidase and 
sulphite oxidase. In this family of proteins, Mo occurs as Moco, in which Mo is bound to 
a unique tricyclic pterin structure (Schwarz, 2005). Mo is the only transition metal of the 
second series of Periodic Table known to be essential for mammals. Its chemistry is perhaps 
the most complex of all transition metals. Mo has found its way to biochemical systems 
most likely because of its easy redox conversions in aqueous environments (ranging from 
oxidation state IV to VI). Unlike many other transition metals Mo appears in biological 
systems as an anion, e.g. MoO24.  
- 
Molybdenum is generally less toxic in comparison with other transition metals. Excessive 
Mo intake has occurred in geologically distinct areas of Russia and results in increased 
xanthine oxidoreductase activity, high urate levels and gout-like symptoms. These effects 
are opposed by copper ions, and more specifically by tungstate. Tungstate can replace 
molybdate in the enzyme during Mo deficiency, which has been used experimentally to 
inhibit XOR in vivo (Brown et al., 1988).
Because of its vulnerability to degradation by oxygen, Moco is not believed to exist as 
a free compound in mammalian cells. Without a protective environment provided by an 
apoenzyme, the half-life of Moco at neutral pH is only a few minutes (Nason et al., 1971). 
Enzymes involved in Moco synthesis are highly conserved in all cells. In humans Moco 
deficiency (MIM 252 150), leading to deficiency of XOR, AO and sulphite oxidase, is fatal 
in early childhood due to sulphite accumulation in the central nervous system (Schwarz et 
al., 2004).
2.8.4 Conversion of XDH to XO
Initially the XOR protein is translated as XDH, which is subject to post-translational 
modifications converting XDH to the XO isoform with concomitant changes in enzyme 
activity and specificity. The conversion is reversible when it involves the formation of 
a disulfide bridge by oxidation of -SH moieties of critical cysteine residues. XOR has a 
cluster of cysteins, which makes the enzyme redox sensitive. 
There are data to suggest that XDH and XO are at thermal equilibrium, and proteolysis 
or thiol oxidation can then lock the protein in XO isoform. (Nishino et al., 2005). The 
irreversible conversion of XDH to XO results from proteolysis of a linker peptide, which 
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connects the molybdenum and NAD domains. For example, Ca-proteases and trypsin can 
cleave a 20 kDa fragment from the enzyme resulting in an irreversible conversion. These 
changes may take place even in vitro, for example by the disruption of lysosomes during 
purification, thus leading to artificially high XO activity. This type of conversion can be 
prevented in vitro by the use of protease inhibitors, such as leupeptin.
Proteolytic cleavage of the enzyme takes place in a variety of conditions. During 
ischemia XOR is converted to the ROS producing isoform XO. Restoration of circulation 
increases oxygen availability, which is accompanied with XO catalyzed ROS production 
(Parks et al., 1988). During ischemia ATP is degraded to AMP and then further to xanthine 
and hypoxanthine. This process provides an increased substrate availability for XO. Low 
oxygen tension has been reported not only to induce XOR, but also to increase XDH to 
XO conversion. This type of setting is referred to as ischemia-reperfusion or I/R, and is 
often associated with tissue damage (McCord, 1985). As the lack of oxygen is a powerful 
regulator of metabolic and cellular events, I/R is a complex process involving a plethora of 
stress induced factors.
Transformation may take place in mucosa in association with the common cold caused 
by Rhinoviruses. The Rhinovirus infection has been reported to induce conversion of XDH 
to XO. Serine proteases are involved as the conversion was inhibited by aprotinin and 
leupeptin, but not by inhibitors of metalloproteinases. During rhinovirus infection of 
primary human bronchial epithelial cells, ROS generated by XO depleted cellular GSH 
stores thus shifting the redox balance to favor oxidative XDH to XO conversion. This in 
turn creates a vicious cycle which was found to be harmful to the infected cells (Papi et al., 
2008). The authors reported that oxypurinol, a specific XOR inhibitor, not only decreased 
ROS production substantially, but also prevented virus proliferation in cell culture.
2.8.5  XOR, nitrate, nitrite and nitric oxide
Although it was already known in 1924 that XOR reduces nitrate to nitrite, there has 
afterwards been a long-lived tenet, according to which nitrate is not metabolized by 
mammalian cells. Nitrite has traditionally been regarded as a bacterial metabolite of nitrate. 
Circulating nitrate is derived from dietary sources and NO metabolism (Lundberg and 
Weitzberg, 2005). In clinical studies, nitrate levels correlated negatively with plasma levels 
of an endogenous NOS inhibitor, asymmetric dimethyl arginine (Päivä et al., 2006).
Jansson et al. (2008) have recently demonstrated that germ-free mice are also able to 
produce nitrite from nitrate. Allopurinol treatment was shown to reduce 40 – 80% of 
nitrate reductase activity in mouse, rat and human liver homogenates. In murine tissues 
greatest effects were found in the liver, the intestine and the kidney, while in the lung and 
cardiac tissues allopurinol did not have any effect on nitrate reduction (Jansson et al., 2008, 
Tripatara et al., 2007). These results are in line with XOR distribution, which has been 
covered in Section 2.9.4.
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Evidence has been obtained indicating that even NO can be generated enzymatically 
from nitrite. Zhang et al. (1997, 1998b) were first to show that XO is able to convert nitrite 
ions into NO. Furthermore, XDH tertiary structure was noted to resemble that of bacterial 
nitrate reductase (EC 1.6.6.1), which is also a Moco enzyme. 
Human studies have suggested generation of NO by erythrocyte bound XOR (Webb 
et al., 2008a). Recent reports by Li et al. (2008) demonstrated that along with XOR, AO 
is another enzyme capable in producing NO. Li et al. (2008) provided evidence indicating 
that nitrite reduction does not take place in blood, but in tissues. The generation of NO 
from nitrite by AO and XOR is regulated by pH, oxygenation, nitrite levels and redox 
balance. These features indicate that the nitrite pathway could be an alternative NO source 
in hypoxic conditions. The oxygen in NO molecules are derived from molecular oxygen 
when NO is generated from L-arginine by NOS (Leone et al., 1991). 
Experimentally, the reaction producing NO from nitrite has been demonstrated within 
(or near) physiological levels of nitrate and nitrite, and also when tissue oxygen levels are 
not compromised (Jansson et al., 2008). In liver homogenates from rats nitrite formation 
from nitrate was not inhibited by L-NAME, suggesting that nitric oxide synthases were not 
involved. In line with these observations, nitrate has been reported to transiently lower SBP 
in rats even during coadministration of the NOS inhibitor, L-NAME (Kanematsu et al., 
2008). Casey et al. (2008) found that i.v. administration of nitrite i.v. decreased transiently 
both pulmonary and systemic arterial pressure and increased cardiac output in Sprague-
Dawley rats by allopurinol-sensitive mechanisms, which were not blocked by L-NAME.
Recent studies by Webb et al. (2008b) demonstrated a transient blood pressure lowering 
effect from beet juice, which contained high levels of nitrate. Nitrate is continuously 
excreted into saliva. The decrease in SBP was blocked by collection of saliva, which impedes 
conversion of nitrate to nitrite by nitrate reductases of oral anaerobic bacteria.
The use of organic nitrates is a cornerstone in the treatment of ischemic heart disease. 
Development of nitrate tolerance limits the usefulness of organic nitrates, including glycerol 
trinitrate. Development of nitrate tolerance is a complex phenomenon. Mitochondrial 
aldehyde dehydrogenase (ALDH2) is a redox sensitive enzyme, which yields nitrate from 
the nitro moiety of many organonitrates. Downregulation of ALDH2 has been associated 
with nitrate tolerance. There is evidence that also XOR is capable to activate organic 
nitrates to NO in the presence of thiols and ascorbate (Doel et al., 2001, Li et al., 2005). As 
nitrite has been shown to be an active metabolite of organonitrates, it has been suggested 
as a therapeutically useful agent to bypass tolerance to organic nitrates (Dejam et al., 2007). 
In their human study, the authors reported that oxopurinol failed to inhibit vasodilation 
induced by nitrite infusion, but on the contrary potentiated vasodilation, indicating that 
the role of XOR in NO production has not been fully elucidated.
NO exerts most of its effects principally by nitrosating molecules, e.g. generating 
nitrated derivative of guanylyl cyclase, reacting with glutathione residues in hemoglobin 
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and producing covalently nitrated thiols in cystein moieties in many proteins (Foster et al., 
2003; Bohlen et al., 2009). NO has been reported to inhibit XOR, but whether this takes 
place also in vivo has not been clarified (Khan et al., 2004). Urate has been reported to 
react with NO. Nitrosated urate can transfer NO to glutathione and may act as a carrier 
molecule for NO and prolong NO half-life (Suzuki, 2007). The reaction of a superoxide 
anion with NO produces peroxynitrate, which is able to react with tyrosine moieties of 
proteins. Urate was shown to effectively compete with tyrosine, and to protect the heart 
from protein nitration (Teng et al., 2002). Nitrate is a stable molecule and it has been 
suggested to participate in the long-term regulation of NO via XOR mediated pathways 
(Lundberg et al., 2008). So far all experimental and human cardiovascular studies on nitrite 
have reported transient SBP lowering effects.
2.8.6 Fructose and XOR
Fructose is one of the dietary factors, which increases urate production. In high acute doses 
fructose can induce acidosis and hypoglycaemia in subjects with fructose intolerance and to a 
lesser extent also in tolerant subjects. Fructose and its congeners are rapidly phosphorylated 
to fructose-1-phosphate, a reaction which consumes ATP and increases ATP metabolism 
with a concomitant increase in purine substrates for XOR and subsequent increases in 
urate production (Laakso et. al. 2003).
In animal models fructose feeding induces hypertension. In contrast to glucose, fructose 
does not exert normal insulin and leptin response. Chronic fructose feeding in rats has 
been reported to induce leptin resistance and substantial obesity, thus providing an animal 
model for metabolic syndrome (Oron-Herman et al., 2008). Obesity is associated with 
sustained increases in blood pressure. In addition, obesity is accompanied with altered 
renal function, increased reabsorption of sodium, sympathetic outflow and compression 
of the kidney which is anatomically surrounded by adipose tissue (reviewed by Hall 2003). 
Experimental studies have indicated that hypercholesterolemia can modify renal function 
(Minami et al., 2005).
As fructose and its congeners are widely used in food industry, they have been suggested 
as one of the underlying factors contributing to increased prevalence of metabolic syndrome 
(Johnson et al., 2007). In contrast to experimental studies, the first epidemiological studies 
have failed to confirm an association of fructose intake with SBP (Forman et al., 2009).
2.8.7  Roles of XOR beyond purine metabolism
While XOR is the key enzyme involved in the last steps of purine metabolism, it has 
become increasingly evident that the enzyme also has many other biological functions. 
Upon its discovery XOR or the ‘Schardinger enzyme’, was found to catalyze (in milk) the 
discoloration of methylene blue in the presence of aldehydes. Twenty years later there was 
vivid discussion in the literature concerning whether nitrate reduction (in the presence 
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of aldehydes, hypoxanthine and xanthine) could be catalyzed by the same ‘Schardinger 
enzyme’ (Dixon and Thurlow, 1924). Since then new features relating to biological roles 
of XOR have been discovered. Established and emerging biological roles for XOR are 
summarized in Table 2.
XOR has a broad specificity towards reducing substrates, including purines, numerous 
aromatic heterocycles and aldehydes. The role of  XOR in pteridine metabolism is depicted 
in Figure 5, including the reaction which has often been used to determine XOR activity.
In addition to its most important endogenous substrates hypoxanthine and xanthine, 
XOR is involved in the metabolism of ethanol and a variety of xenobiotic compounds. 
Thiopurines are also good substrates for XOR. Azathioprine is an immunosuppressive 
prodrug, which is first converted to 6-mercaptopurine in the liver and subsequently 
transformed to a pharmacologically active purine species. XOR is able to metabolize 
6-mercaptopurine to 6-thiouric acid and inactivate the pharmacological effects of 
azathioprine. The co-administration of allopurinol has allowed lower azathioprine doses 
with less hepatotoxicity (Ansari et al., 2008).
Figure 5. Xanthine oxidoreductase catalyzed reactions in pterin metabolism, which can be  
inhibited by allopurinol. The conversions not labelled with XOR are nonenzymatic. The reaction 
which has been used in determination of XDH and XO is marked in red (Beckman et al., 1989). 
BH4, i.e. 5,6,7,8-tetrahydropterin is a cofactor of NOS (Hurshman and Marletta 2002).
2.8.8 Human xanthine oxidoreductase
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catalyze (in milk) the discoloration of methylene blue in the presence of aldehydes. 
Twenty years later there was vivid discussion in the literature concerning whether 
nitrate reduction (in the presence of aldehydes, hypoxanthine and xanthine) could be 
catalyzed by the same Ô Schardinger enzymeÕ  (Dixon and Thurlow, 1924). Since then 
new features relating to biological roles of XOR have been discovered. Established 
and emerging biological roles for XOR are summarized in Table 2. 
XOR has a broad specificity towards reducing substrates, including purines, 
numerous aromatic heterocycles and aldehydes. The role of XOR in pteridine 
metabolism is depi ted in Figure 5, including the reaction which has of en been used 
to determine XOR activity. 
In addition to its most important endogenous substrates hypoxanthine and 
xanthine, XOR is involved in the metabolism of ethanol and a variety of xenobiotic 
compounds. Thiopurines are also good substrates for XOR. Azathioprine is an 
immunosuppressive prodrug, which is first converted to 6-mercaptopurine in the liver 
and subsequently transformed to a pharmacologically active purine species. XOR is 
able to metabolize 6-mercaptopurine to 6-thiouric acid and inactivate the 
pharmacological effects of azathioprine. The co-administration of allopurinol has 
allowed lower azathioprine doses with less hepatotoxicity (Ansari et al., 2008). 
 
 
Figure 5. Xanthine oxidoreductase catalyzed reactions in pterin metabolism, which can be 
inhibited by allopurinol. The conversions not labelled with XOR are nonenzymatic. The 
reaction which has been used in determination of XDH and XO is marked in red (Beckman et 
al., 1989). BH4, i.e. 5,6,7,8-tetrahydropterin is a cofactor of NOS (Hurshman and Marletta 
2002). 
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Table 2. Established and emerging physiological roles of XOR. 
Physiological 
function 
Features Reference 
Purine 
metabolism 
Production of uric acid. Inhibited by AP or oxopurinol, 
febuxostat and high WO4-/low MoO4- diet. 
Morgan et al., 1922 
Metabolism of 
(BH4) 
Degradation of 5,6,7,8 tetrahydro-biopterin (BH4) to 
pterin to isoxanthopterin. BH4 is NOS cofactor.  
Blair, 1957; Beckman 
et al., 1989; Blau et 
al., 1996 
Xenobiotic 
metabolism 
Aldehydes, several drugs, nitrofuran derivatives, 
heterocycles, thiopurines.  
Kitamura et al., 2006; 
Ansari et al., 2008 
Ferreoxidase,  Incorporation of Fe into transferring 1000-fold more 
active than caeruloplasmin. High WO4-/low MoO4-, 
HCN and MeOH inhibits. XO has higher activity than 
XDH. pH optimum corresponds to intestinal mucosa. 
Topham et al., 1980; 
Hall-Sizemore et al., 
1994 
Nitric 
reductase 
NO3- to NO2- to NO, nitrosothiols to NO. Inhibition by 
high O2 levels, allopurinol, oxypurinol. Organic nitrates 
to NO. Inhibition by DPI, but not by AP. 
Li et al., 2005; Jansson 
et al., 2008; Webb et 
al., 2008a 
Retinol 
metabolism 
all-trans-retinol to all-trans-retinaldehyde in human 
mammary epithelial cell line, inhibits viral replication 
Taibi and Nicotra, 
2007 
NADH oxidase DPI inhibits, AP does not, indicating that Moco is not 
involved. XDH has higher activity than XO.  
Sanders et al., 1997; 
Zhang et al., 1998a; 
Maia et al., 2007 
Interaction 
with nNOS 
nNOS -/- mice have upregulation of XOR in cardiac 
tissue. XOR and nNOS have the same localization in 
cardiac myocytes. 
Khan et al., 2004 
Regulation of 
renal COX-2 
30-fold upregulation of XOR during renal development 
concomitantly with COX-2. XOR -/- mice have strikingly 
similar renal phenotype as COX-2 knockout mice. 
Ohtsubo et al., 2004 
Adipogenesis Regulation of PPARγ by XOR Cheung et al., 2007 
Structural 
element in milk  
XDH and butyrophilin are indispensable for milk fat 
excretion. Fat excretion impaired in XOR-/+ mice (XOR-
/- mice died). XOR colocalizes with adipophilin. 
McManaman et al., 
2002 
Innate immune 
function 
XOR is expressed in epithelial and endothelia surfaces 
and closely associated with TLR-NF-kappa-B pathways 
and directly activated by NF-κ-B and AP-1. 
Vorbach et al., 2003 
Immune 
function 
Production of bactericidial ROS and adjuvant urate in 
epithelium. Virus-induced protelolysis of XDH to XO. 
Vorbach et al., 2003; 
Papi et al., 2008 
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In spite of high circulating urate levels, human XOR activities are approximately one 
hundredfold lower than in rodents. Post mortem studies have indicated that XOR 
is occasionally found in the kidney and the lung, whereas in the human plasma, brain 
and heart XOR is undetectable (Sarnesto et al., 1996; Kinnula et al., 1997; Saksela et al., 
1998). These and similar studies led to a decline of interest in clinical studies, which had 
concentrated on XOR as a potential drug target in myocardial ischemia (Brown et al., 
1988).
Analyses have been carried out in whole tissues, leading to dilution of the enzyme, if most 
activity is found only on the endothelial wall of blood vessels. XOR binds to endothelium via 
glycosaminoglycans. Endothelium bound XOR can be liberated to circulation by heparin 
bolus and can subsequently be determined from plasma by monitoring O2- generation 
with and without oxopurinol by using electron spin trapping techniques (Spiekermann et 
al., 2003). 
XOR activity in human milk peaks during first weeks post partum and declines 
thereafter. At this later phase it has been shown to have equivalent NADH oxidase 
activity as bovine enzyme, indicating that the FAD site of the enzyme is comparable. 
Mo content of human XOR is less than 10% in comparison with bovine enzyme and 
it contains only 30% of the Fe-S clusters found in the bovine enzyme. Also xanthine 
molecular activity by human enzyme was found to be less than 10% that of bovine 
enzyme (Godber et al., 2005).
Human XOR deficiency (MIM 278 300) is not fatal. Literature addressing other 
characteristics other than xanthinuria, for example immune function in XOR deficient 
humans, is scarce.
2.8.9 Cardiovascular studies on XOR inhibition
Clinical and experimental studies on the effects of XOR inhibition published before 2006 
have been recently reviewed (Pacher et al., 2006). Most experimental studies have modelled 
myocardial infarction by using an I/R setting. Of these studies 19 reported positive effects 
when infarct size was chosen as an endpoint, whereas 7 studies reported failures of reduction 
in infarct size. Clinical studies reviewed in the same article have more disconcordant results, 
partly because of different clinical settings and surrogate end-points. In six studies out of 
eight, some level of cardioprotection was reported.
Although XOR activity in human tissues is low, recent studies with electron spin resonance 
techniques indicate that XOR activity is inducible also in human tissues. Spiekerman et al. 
(2003) reported a marked (>200%) increase in endothelial XOR activity in patients with 
angiographically documented coronary artery disease (CAD), in comparison with age-
matched controls. Furthermore, the authors demonstrated XOR and NAD(P)H oxidase 
induced production of ROS.
In line with studies reviewed by Pacher et al. (2006), recent experimental studies 
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with rodent models point towards that XOR inhibition may exert beneficial effects on 
cardiac function, see Table 3. There are ongoing clinical studies in which potential use of 
allopurinol in cardiovascular disease will be investigated. While studies on rodent models 
have given a positive overall picture, the outcome in reported clinical studies have been 
variable, although some of them show positive effects. Generally, the studies so far have been 
relatively limited, except the OPT-CHF study in which 405 patients with cardiac failure 
of NYHA class II-IV were studied. The outcomes of most recent studies are summarized 
in Table 4.
Relative high allopurinol or oxopurinol doses have been used in experimental and 
clinical studies on cardiovascular effects of XOR inhibition. Dose levels have been more 
than would be needed for XOR inhibition. Consequently the effects of these drugs on 
other metabolic pathways may become important. Studies employing other XOR inhibitors 
(except allopurinol or oxopurinol) are scarce. Recently Sánches-Lozada et al. (2008) have 
reported SBP lowering effects of Febuxostat, a potent non-purine XOR inhibitor, in an 
experimental hyperuricemic rodent model of hypertension.
Microparticles are circulating lipid vesicles, generated by blebbing of plasma membrane 
from apoptotic cells and also from non-apoptotic cells in response to various stimulae. The 
concentration of microparticles is increased in various pathophysiological states including 
myocardial infarction and end-stage renal disease. Microparticles derived from human 
lymphoid cell culture induced endothelial dysfunction with increases in ROS production 
and decreases in NO availability. These effects are inhibited by XOR inhibitors and also by 
inhibitors of phosphoinositol-3-kinase (Mostefai et al., 2008).
To summarize Section 2.8: XDH is a protein derived from translation and is subject to 
several post-translational modifications. The interconversion of XDH and XO isoforms has 
been suggested to have a biological role, because the conversion is a complex phenomenon 
and appears to involve thermal equilibrium. Several factors, including Ang II, cytokines, 
hypoxia, intracellular iron and lactogenic hormones, regulate XDH expression. In addition 
to its important house-keeping role in purine and pterin metabolism, XOR has several 
other functions, including detoxification of exogenous compounds. XOR derived ROS can 
also scavenge NO and may participate in the activation of organic nitrates. Human XOR 
has lower Moco content than that found in rodents. XOR protein levels and human XOR 
activities are also generally much lower than those found in rodents. Evaluation of the role of 
XOR in cardiovascular phenomena is complex due to multiple roles of the enzyme. XOR can 
produce NO and ROS, which together generate reactive nitrogen species, important for innate 
immunity. Recent experimental studies have indicated positive cardiovascular effects of XOR 
inhibition, including reduction of infarct size and alleviation of hypertension induced left 
ventricular hypertrophy. However, results from clinical studies have been more variable.
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Table 3. Experimental studies on XOR inhibition since 2006. Earlier studies have been 
reviewed by Pacher et al. (2006). 
Experimental studies Effects Reference 
Pressure overload-induced 
(transverse aortic 
constriction) LVH and 
dysfunction in C57/BL6 mice 
Febuxostat 5 mg/kg/d 8d. 
Attenuation of TAC-induced changes in LV 
ejection fraction, LV end-diastolic posterior wall 
thickness, LV diameter at end systole. Plasma 
uric acid levels decreased from approx 0.75 mg/L 
to approx. 0.1 mg/L. 
Xu et al., 
2008 
TO-2 hamster (deficient in δ-
sarcoglycan). Model of 
dilated cardiomyopathy. 
Allopurinol (30 mg/kg/d, 6 
weeks). 
Attenuation of LV dysfunction and dilation, 
myocardial fibrosis and the upregulation of a 
fetal-type cardiac gene. Inhibition of decrease in 
GSH/GSSG ratio and the increase in 
malondialdehyde levels in the heart. 
Hayashi et 
al., 2008 
L-NAME induced 
hypertension and LVH in 
Wistar rats. Allopurinol 40 
mg/kg/d 5 weeks. 
Allopurinol alleviated left ventricular hypertrophy 
without interfering with L-NAME induced 
hypertension 
Kasal et al., 
2008 
Cocaine-induced cardiac 
dysfunction in Wistar rats. 
Allopurinol (50 mg/kg, 7 
days) resulted in 60% 
decrease in XOR activity. 
Inhibition restored fractional shortening, cardiac 
output and stroke volume. Apocynin (50 mg/kg) 
also tested with positive results. Apocynin 
downregulated XOR, but did not influence 
NAD(P)H. 
Isabelle et 
al., 2007 
Nitrite induced 
cardioprotection of in vivo 
and ex vivo rat (SD) models 
of myocardial ischemia. 
Oxypurinol 10 µmol/L or DPI 
2 µmol/L in perfusate. 
Recovery of left ventricular developed pressure 
and reduction of infarct size. XOR inhibitors 
abolished nitrite induced cardioprotection, while 
NOS inhibitor did not. Putative NAD(P)H oxidase 
inhibitor, apocynin, had the same effect as 
allopurinol. NAD(P)H oxidase not measured. 
Baker et al., 
2007 
Pigs fed with high-cholesterol 
diet for 12 weeks. Intrarenal 
oxypurinol infusion at 300 
mg/min/kg for 15 min. 
Transient intrarenal infusion of oxypurinol 
resulted in significantly improved renal perfusion 
response to an endothelium-dependent challenge 
as compared with controls. 
Daghini et 
al., 2006 
Transgenic TnI-(1–193), 
which display myocardial 
stunning, a model of 
progressive cardiomyopathy. 
Allopurinol in drinking water 
260 mg/L, 1-2 months 
Abolishment of relative left ventricular weight 
increase. Cardiac function determined by 
electrocardiography, marked improvement of Ca2-
-activated twitch tension. Nearly complete 
inhibition of XOR in cardiac tissue. 
 
Duncan et 
al., 2005 
Reversal of CsA side effects 
by allopurinol 
Alleviation of CsA-induced arterial blood pressure 
and renal blood flow in rats. 
Kobelt et al., 
2002 
 
Table 3. Experimental studies on XOR inhibition since 2006. Earlier studies  
have been reviewed by Pacher et al. (2006).
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Table 4. A few recent clinical studies involving XOR inhibitors. Earlier studies prior to 2006 have 
been reviewed by Pacher et al. (2006) 
Clinical studies Effects Reference 
Randomized, double-blind, 
placebo controlled study; 
patients recruited within 72 
hrs of radiologically 
confirmed ischemic stroke. 
Two allopurinol dose 
regimen: 100 mg/d and 
300 mg/d for 6 weeks. 
Positive changes in surrogate markers 
with higher allopurinol dose: attenuation 
of ICAM-1 rise after stroke. 17 patients per 
group, mean age 70 yrs. 
Muir et al., 2008 
 
405 patients with NYHA 
class III–IV heart failure and 
LVEF ≤40% were randomly 
assigned to control and 
treatment groups. 
Double-blind treatment with 
either oxypurinol (600 
mg/day) or placebo, for 24 
weeks.  
No improvement in unselected patients 
in spite of decrease in plasma urate 
levels in a composite end-point.  
Post-hoc analyses suggested benefits in 
a patient subgroup with elevated SUA 
and correlated in this group with degree 
of serum urate decrease. 
Evaluation of patient status was based 
on composite clinical end-points 
describing whether status was 
improved, unchanged or worsened. 
Worsening of the condition was based 
on lethal event, hospitalization and 
need for emergency treatment. 
Patients in both groups received all 
appropriate medications, including ACE 
etc. 
 
Hare et al., 
2008 
Patients with systolic, 
symptomatic heart failure. 
Oxypurinol 
No clinical improvement in a clinical 
composite score of unselected patients 
with moderate to severe heart failure. 
Benefits occurred in patients with high 
urate levels as revealed by post-hoc 
analyses. 
 
Chaves et al., 
2007 
60 patients (30 per group) 
of NYHA class II-III CHF. 
Double-blind 1 month 
placebo controlled 
treatment with oxypurinol 
(600 mg/day). 
Left ventricular ejection fraction (LVEF) 
improved, but did not reach statistical 
significance (p<0.08). When patients 
with LVEF <40% were excluded from 
analyses LVEF was significantly 
(p<0.02) improved in oxypurinol group. 
Tendency of decreased left ventricular 
mass in oxypurinol group. No effects in 
exercise capacity (6-minute walking 
test). 
Cingolani et al., 
2006 
 
Table 4. A few recent clinical studies involving XOR inhibitors. Earlier studies  
prior to 2006 have been reviewed by Pacher et al. (2006)
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3 Aims of the Study
Experimental studies were designed to clarify in vivo the possible role of XOR in genetic, 
salt-induced hypertension and in metabolic syndrome.
Specifically the aims of the present studies were as follows:
1. To compare hypertension-prone, salt-sensitive rats and their genetically close control 
1. strains in terms of XDH and XO activities and expression particularly in the kidney.
2. To investigate whether renal XDH and XO activities are modified by dietary intake  
1. of NaCl.
3. To resolve whether NO regulates XOR in vivo.
4. To clarify whether XOR has any causative role in hypertension.
5. To find out whether chronic administration of immunosuppressive drug, CsA,  
1. at nephrotoxic dose levels, with or without increased NaCl intake, regulates renal  
1. XOR activity.
6. To investigate the role of XOR in metabolic syndrome using obesity-prone  
1. rat models.
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4 Material and methods
 
4.1 animals and treatments
All animal experiments were carried out according to study protocols approved by the 
Animal Experimentation Committee of the Institute of Biomedicine at University of 
Helsinki to meet the standards set by the American Physiological Society and by Helsinki 
Agreement.
In all experiments, the rats were obtained from (Harlan-Spraque-Dawley, Indianapolis, 
IN, USA) and kept four animals per cage in standardized conditions (illuminated from 
6.30 a.m. until 6.30 p.m., room temperature 22 ± 1 °C).
Experimental and control groups were matched on basis of their blood pressure and 
body weight. In all experiments the rats had free access to tap water and chow. In the 
following studies a ‘low NaCl’ diet refers to mean standard laboratory rat diets which 
generally contained 0.2 – 0.7% NaCl. In addition a ‘high’ NaCl diet in this context refers 
to a standard diet, which has been supplemented with NaCl. The levels have been specified 
separately in each study.
 
Study I
Forty-five, three-week-old Dahl salt-sensitive (SS/Jr) and salt-resistant (SR/Jr) male rats 
were assigned to four weight-matched subgroups of each strain to be kept for seven weeks 
on diets differing in sodium content. Diets containing 0.05%, 0.20%, 3.25% and 6.50% 
NaCl (w/w) (corresponding to 0.02, 0.08, 1.28, and 2.56% as Na+), were prepared by 
mixing NaCl into a special low sodium laboratory chow (TD90228, Harlan Teklad division, 
Indianapolis, IN, USA).
Twelve male eight-week-old SHR Okamoto rats and 10 WKY male rats were assigned to 
two groups, respectively, to be kept for eight weeks on low (0.20% w/w NaCl, corresponding 
to 0.08% Na+ w/w) or high (6.50% NaCl w/w, i.e. 2.56% as Na+) NaCl diets.
In a separate, previously unpublished (Laakso, Pere, Lapatto) experiment fourteen 
SHRs were assigned into two groups and were kept six weeks on low (0.20% w/w NaCl) 
or high (6.2% w/w NaCl) NaCl diets. Kidney and left ventricular samples were frozen 
immediately after excision and stored at -70 °C prior to analysis.
 
Study II
Forty-seven, nine-week old male SHRs were randomly allocated to six subgroups. The 
groups were kept three weeks on three different diets containing 0.08, 0.4 or 2.4% of Na+ 
(w/w of the diet, added as NaCl, JozoTM, Akzo Salt, Amersfoort, the Netherlands) with 
or without N-nitro-L-arginine methyl ester (L-NAME, Sigma Chemical Co, St Louis, 
USA) L-NAME was given at a concentration of 250 mg/kg (w/w) of the chow providing 
approximately 20 mg/kg bw/day.
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Another forty male SHRs, nine weeks of age, were randomly allocated to six groups and 
kept for eight weeks on either 0.3%, or 1.4% Na+ diet [0.76% and 3.56% NaCl (w/w) in 
the diet], and respective groups kept on the same diets with 100 mg/kg of chow isosorbide-
5-mononitrate (IS-5-MN), providing approximately 65 mg/kg body weight/day.
 
Study III
Fifty Wistar–Kyoto (WKY) rats and 49 Okamoto-Aoki spontaneously hypertensive rats, 
five weeks of age, were acclimatized for one week and fed with standard rat chow containing 
0.3% NaCl (w/w). At the onset of the experiment, six rats of each strain were killed and the 
remaining animals were divided into groups of low and high NaCl diets with or without 
allopurinol. Animals were killed three, five and eight weeks after the onset of the study. 
Immediately after death, the liver and the kidneys were removed. 
The low NaCl diet (Finnewos Aqua, Helsinki, Finland) contained 0.3% NaCl (w/w). 
The high NaCl diet was prepared by adding NaCl to a final concentration of 6% (w/w). 
Respective diets containing 62.5 mg of allopurinol / kg of chow (E. Merck, Darmstadt, 
Germany) were prepared. As calculated from the chow consumption, the diets containing 
allopurinol provided approximately 21 mg / kg body weight at the onset and 10 mg / kg of 
allopurinol at the end of the experiment.
 
Study IV
Thirty-three female obesity-prone Zucker rats (Harlan, Oxon, UK) were used. Rats were 
matched for blood pressure and serum cholesterol, and were divided into three groups to 
receive different diets. Eight lean Zucker rats served as control group and consumed basic 
dry rat food (Altromin, Lage, Germany). The same control diet was given to the obese 
Zucker controls. The second obese group received valsartan, which was added into the 
diet at a level of 12 mg/kg of chow. The atherogenic diet group consumed the same food 
into which 18% butter was incorporated (Valio, Helsinki, Finland), 1% cholesterol (Sigma, 
St. Louis, MO, USA), and 6% NaCl (w/w) (University Pharmacy, Helsinki, Finland). 
Valsartan was a generous gift from Novartis Ltd., Basel, Switzerland.
 
Cyclosporine experiment
Fifty SHRs, eight-week of age, were divided into seven blood pressure and body weight 
matched groups of 6–8 animals to be kept on different diets for six weeks with or without 
s.c. administration of CsA (Sandimmun). The dose level was 5 mg/kg or in case of 
controls, an equivalent amount of diluted Intralipid solution used as the vehicle. Three 
dietary protocols were used. A low NaCl diet comprising of standard laboratory chow 
(R36, Finnewos Aqua, Helsinki, Finland) containing 0.76% NaCl (w/w), a high NaCl 
diet containing 6.5% NaCl (w/w) and a Mg-supplemented diet containing the same 
amount of NaCl, 6.5%, as the high NaCl diet, but had three times higher Mg2+ level, 
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0.6% (w/w), than the standard diet. MgCl2 was obtained from E. Merck, Darmstadt, 
Germany.
Functional parameters, such as blood pressure, renal function data and tissue electrolyte 
levels have been published earlier in detail (Mervaala et al., 1997).
 
Tissue samples
At the end of the experiments, the rats were anesthetized with a mixture of CO2 (70%) and 
O2 (30%), (Aga Ltd, Riihimäki, Finland) and decapitated. Blood samples were obtained 
following decapitation and blood plasma with EDTA as anticoagulant was separated by 
centrifugation at room temperature. The kidneys and the heart were removed and washed 
with ice-cold saline solution, frozen immediately in liquid nitrogen, then lyophilized and 
kept at –20 °C in vacuo (Study I and CsA study) or kept at –80  °C (Studies II, III and IV).
4.2 blood pressure measurement
The systolic blood pressures of unanesthetized rats were measured with a tail-cuff pressure 
analyzer (Apollo-2AB Blood Pressure Analyzer, Model 179–2AB, IITC Life Science). The 
analog signals obtained were converted to digital values by an on-line microprocessor. 
Before collecting the recordings, the rats were warmed for 10 to 15 minutes at 28  °C to 
make the pulsations of the tail artery detectable. Values for systolic blood pressure and 
heart rate were obtained by averaging results from 3 to 5 measurements. To minimize stress-
induced fluctuations in blood pressure, all measurements were randomly taken by the same 
person at the same time of day (9 to 12).
4.3 biochemical determinations
4.3.1 Assays of enzyme activities of XO and XDH
Lyophilized (Study I and CsA study) or frozen (Study II, III and IV) kidneys and other 
tissues were homogenized in phosphate buffer, pH 7.4. Buffer compositions can be found 
in the Material and Method Sections of Studies I–IV. EDTA, DTT, and proteinase 
inhibitors were used to protect proteins from oxidation and free metal ions. Homogenates 
were ultracentrifuged (100 000g, one hour), and supernatants were passed through a gel 
filtration column (Biogel P10, Bio-Rad, CA, USA) to remove small interfering molecules. 
XO and XDH were measured fluorometrically (Beckman et al., 1989) in Studies I, II 
III and in the CsA study. The determination was based on the xanthine oxidase-catalyzed 
conversion of pterin (2-amino-4-hydroxypteridine) to isoxanthopterin.
Radio-HPLC assay was employed in Study IV. XOR activity was measured by using 
[14C]xanthine as the substrate. After separation of the produced uric acid by HPLC 
(Shimazu Co, Kyoto, Japan), its radioactivity was recorded with a Radiomatic Flow 
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Scintillation Analyzer (Packard Instrument, CT, USA) as described elsewhere (Saksela et 
al., 1998). For total XOR activity (XDH + XO), NAD+ (400 µM) was present, whereas for 
XO assay, NAD+ was omitted. In all studies, total protein was determined with the biuret 
protein assay (Bio-Rad, CA, USA).
Intra-assay imprecision of the total activity was not more than 5%. One unit of XOR, 
XDH or XO activity is defined as 1 µmol isoxanthopterin formed per minute and 1 µmol 
uric acid formed in the case of radio-HPLC method.
 
4.3.2 RNA analyses by Northern blot
Total liver and kidney RNA was extracted from randomly selected specimens of 10-week-
old rats by the guanidinium thiocyanate–caesium chloride method (Chirgwin et al., 1979). 
Subsequently, mRNA was extracted using the Oligotex mRNA kit (Qiagen, Hilden, 
Germany). To quantify XOR mRNA, Northern blot analysis was performed as described 
elsewhere (Martelin et al., 2002). Membranes were hybridized using standard procedures 
(Sambrook et al., 1989) with 32P-labelled complementary RNA probe, including two 
fragments corresponding to nucleotides 118–2985 of the rat XOR cDNA (kindly provided 
by Professor T. Nishino, Nippon Medical School, Tokyo, Japan) (Amaya et al., 1990). 
The same membranes were re-probed with 32P -labelled glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) RNA probe transcribed from the pTRI-GAPDH plasmid 
(Ambion, Austin, TX, USA) to control the RNA loading, except for Study IV, where S18 
ribosomal RNA was used instead. The X-ray films were scanned with a digital scanner and 
analysed with Scion Image beta 4.0.2 analysis software (Scion, Frederick, MD, USA).
4.3.3. Plasma arginine
Plasma arginine was determined in Study II as described in detail previously (Päivä et al., 
2002). Briefly, arginine was determined fluorometrically as a o-pthalaldehyde derivative 
after reversed phase HPLC with homoarginine as an internal standard. Arginine was 
isolated with Bond-Elut silica solid phase extraction columns prior to derivatization.
4.3.4. Other biochemical assays
Several NAD(P)+ dependent enzymes were also determined spectrophotometrically from 
the kidney and liver samples as described in detail in Study I and II. These enzymes included 
G6PDH, LDH and ALDH. ALDH has several isoenzymes, as described at www.aldh.org 
. As far as photometric activity determination is concerned, there are two ALDH isoforms, 
cytosolic ALDH1 and mitochondrial ALDH2. The level of substrate was chosen according 
to the enzyme with the highest Km, to determine total activity of both isoforms from tissue 
homogenates. The Km for ALDH1 is 500–600 times higher than that of ALDH2. 
In Study IV serum lipids and glucose from the samples taken at the end of the 
experiments were analyzed by an accredited laboratory, United Laboratories Ltd., Helsinki, 
52
Finland (Hitachi 912 Automatic Analyzer, Hitachi Ltd. Tokyo, Japan, all reagent kits were 
obtained from Boehringer Mannheim). Serum total cholesterol was determined with an 
enzymatic method (CHOD-PAP -method), serum HDL cholesterol with an enzymatic 
direct method (HDL-Chol Plus), LDL cholesterol with an enzymatic direct method 
(LDL-Chol Plus), and triglycerides with an enzymatic method (CHOD-PAP -method). 
All reagents wre obtained from Boehringer Manheim, Darmstadt, Germany.
4.4 statistical analyses
The results are given as the mean ± SEM. ANOVA was applied to test the statistical 
significance for strain and diet effects followed by Duncan’s multiple comparison test for 
comparison of pairs of groups. Linear regression analysis was used to calculate correlation 
coefficients. SPSS/PC statistical software (SPSS version 11.0, SPSS Inc, SPSS Inc Chicago, 
IL, USA) was used for statistical computations.
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5. Results
5.1 NaCl, systemic blood pressure and  
5.1 organ weights (studies i and iii)
Keeping Dahl SS/Jr rats on both the moderately high and high NaCl diets for seven weeks 
markedly elevated systolic blood pressure (Figure 6). Body weights were decreased by 25% 
in Dahl SS/Jr but not in Dahl SR/Jr rats kept on highest NaCl intake level. NaCl restriction 
to 0.05%, w/w (Na+ content of 0.02%) resulted in markedly decreased growth rate in both 
in Dahl SS (112 g) and SR rats (155 g) compared with the groups on the low (0.20%, w/w) 
NaCl diet (0.08% w/w of Na+ in the diet) and having body weights from 272 g to 309 g.
Figure 6. Dose response of NaCl on SBP of salt-sensitive Dahl SS/Jr and salt-resistant 
Dahl SR/Jr rats. Statistical significance has been denoted as follows: *, p<0.05 compared with 
same strain kept on 0.20 NaCl diet; #, p<0.05 as compared to rats of Dahl SR/Jr strain kept on 
0.20% NaCl diet (Study I).
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5.1 NaCl, systemic blood pressure and organ weights (Studies I and III) 
Keeping Dahl SS/Jr rats on both the moderately high and high NaCl diets for seven weeks 
markedly elevated systolic blood pressure (Figure 6). Body weights were decreased by 
25% in Dahl SS/Jr but not in Dahl SR/Jr rats kept on highest NaCl intake level. NaCl 
restriction to 0.05%, w/w (Na+ content of 0.02%) resulted in markedly decreased growth 
rate in both in Dahl SS (112 g) and SR rats (155 g) compared with the groups on the low 
(0.20%, w/w) NaCl diet (0.08% w/w of Na+ in the diet) and having body weights from 
272 g to 309 g. 
 
Figure 6. Dose response of NaCl on SBP of salt-sensitive Dahl SS/Jr and salt-resistant Dahl SR/Jr 
rats. Statistical signific nce has been denoted as follows: *, p<0.05 comp red with same strain 
kept on 0.20 NaCl diet; #,  p<0.05 as compared to rats of Dahl SR/Jr  strain kept on  0.20% NaCl 
diet (Study I). 
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The Dahl SS/Jr rats kept on low NaCl diet (i.e. on standard diet) had approximately 20 
to 30 grams higher body weights, while absolute and relative kidney weights were not 
different from Dahl SR/Jr rats on the same standard diet (Study I).
The SHR on the low NaCl diet had markedly higher SBP compared with the WKY rats 
(Study I). The absolute and relative kidney weights were similar in SHRs and WKY rats 
kept on a low NaCl diet. SHRs kept on high NaCl diets had increased relative renal and 
cardiac weights compared with WKY, whereas body weights did not differ between these 
strains (Study III).
5.2 renal xor in hypertension-prone 
5.2 salt-sensitive rats (studies i and iii)
Dahl rats: Dahl SS/Jr and SR/Jr rats kept for seven weeks on low NaCl diet (0.08% Na+ 
w/w in the diet, i.e. 0.2% NaCl w/w) showed no difference either in blood pressure or in 
renal activity of XDH, XO or XOR (Figure 7). Increased NaCl intake (3.25 and 6.50% w/
w NaCl) resulted in increased renal XDH and XO activity in Dahl SS/Jr rats in a dose-
dependent manner (p<0.001, ANOVA). In contrast, increased NaCl intake had no effect 
on renal XDH, XO activity in the Dahl SR rats (Figure 7). NaCl restriction to deficient 
levels, i.e. 0.05% (w/w NaCl in the diet) resulted in markedly decreased renal XO activity 
both in Dahl SS/Jr and SR/Jr rats compared with the groups kept on a low (0.20%, w/w) 
NaCl diet (Study I).
Figure 7. Effect of different levels of dietary NaCl on kidney XOR in (Dahl SS/Jr) salt-sensitive 
and salt-resistant (Dahl SR,/Jr) rat strains. *, p<0.05 as compared to rats of same strain at 0.2% 
NaCl (i.e. 0.08% Na level in the diet); #, p<0.05 compared with control strain kept on the same 
diet (Study I).
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The Dahl SS/Jr rats kept on low NaCl diet (i.e. on standard diet) had approximately 20 
to 30 grams higher body weights, while absolute and relative kidney weights were not 
different from Dahl SR/Jr rats on the same standard diet (Study I). 
The SHR on the low NaCl diet had markedly higher SBP compared with the WKY rats 
(Study I). The absolute and relative kidney weights were similar in SHRs and WKY rats 
kept on a low NaCl diet. SHRs kept on high NaCl diets had increased relative renal and 
cardiac weights compared with WKY, whereas body weights did not differ between these 
strains (Study III). 
5.2 Renal XOR in hypertension-prone salt-sensitive rats (Studies I and III) 
Dahl rats: Dahl SS/Jr and SR/Jr rats kept for seven weeks on low NaCl diet (0.08% Na+ 
w/w in the diet, i.e. 0.2% NaCl w/w) showed no difference either in blood pressure or in 
renal activity of XDH, XO or X R (Figure 7). Increased NaCl intake (3.25 and 6.50% 
w/w NaCl) resulted in increased renal XDH and XO activity in Dahl SS/Jr rats in a dose-
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levels, i.e. 0.05% (w/w NaCl in the diet) resulted in markedly decreased renal XO activity 
both in Dahl SS/Jr and SR/Jr rats compared with the groups kept on a low (0.20%, w/w) 
NaCl diet (Study I). 
 
Figure 7. Effect of different levels of dietary NaCl on kidney XOR in (Dahl SS/Jr) salt-sensitive 
and salt-resistant (Dahl SR,/Jr) rat strains. *, p<0.05 as compared to rats of same strain at 0.2% 
NaCl (i.e. 0.08% Na level in the diet); #, p<0.  pared with control strain kept on the same 
diet (Study I). 
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Figure 8. Renal and cardiac XDH and XO activities of SHRs kept on low (0.2% NaCl w/w) and 
high (6.2% NaCl w/dry w) NaCl containing diets for six weeks. *, p<0.05 compared with low 
NaCl group. N=7 in both groups (Laakso, Pere, Lapatto, previously unpublished data.)
Spontaneously hypertensive rats (SHRs): SHRs kept for eight weeks on a low NaCl diet 
(0.20% NaCl w/dry w in the diet) had markedly higher kidney XOR activities than WKY 
rats (Table 1). Increased NaCl intake (6.5% NaCl w/w) produced increased kidney XDH 
and XOR in SHRs. Increasing dietary NaCl intake from 0.20% to 6.50% elevated systolic 
blood pressure and relative kidney weight in SHRs but not in WKY rats (Study III).
In a separate unpublished (Laakso, Pere, Lapatto) experiment SHRs were kept 6 weeks 
on low (0.20% w/w NaCl) and high (6.2% w/w NaCl) NaCl diets. The tissue samples were 
stored only a few weeks prior to analysis. This additional study was carried out to investigate 
whether cardiac XOR activity is influenced by dietary salt and resulting hypertension. 
While renal XOR activities were increased with higher NaCl intake, cardiac XOR did not 
show any response (Figure 8).
In addition to XOR another hypoxia-regulated enzyme G6PDH was determined for 
comparison. Renal G6PDH activities were increased in the salt-sensitive Dahl SS/Jr rats 
kept on highest NaCl intake level (6.50% w/w NaCl), whereas in salt-resistant Dahl SR/Jr 
rats any significant effect after variation of NaCl intake levels was not found (Table 5).
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Figure 8. Renal and cardiac XDH and XO activities of SHRs kept on low (0.2%NaCl w/w) and 
high (6.2% NaCl w/dry w) NaCl containing diets for six weeks.  *, p<0.05 compared with low 
NaCl group. N=7 in both groups (Laakso J, Pere A-K, Lapatto R , previously unpublished data.) 
Spontaneously hypertensive rats (SHRs): SHRs kept for eight weeks on a low NaCl 
diet (0.20% NaCl w/dry w in the diet) had markedly higher kidn y XOR activities than 
WKY rats (Table 1). Increased NaCl intake (6.5% NaCl w/w) produced increased kidney 
XDH and XOR in SHRs. Increasing dietary NaCl intake from 0.20% to 6.50% elevated 
systolic blood pressure and relative kidney weight in SHRs but not in WKY rats (Study 
III). 
In a separate unpublishe  (Laakso J, Pere A-K, Lapatto R.) experiment SHRs were 
kept 6 weeks on low (0.20% w/w NaCl) and high (6.2% w/w NaCl) NaCl diets. The tissue 
samples were stored only a few weeks prior to analysis. This additional study was carried 
out to investigate whether cardiac XOR activity is influenced by dietary salt and resulting 
hypertension. While renal XOR activities were increased with higher NaCl intake, cardiac 
XOR did not show any response (Figure 8). 
In addition to XOR anoth r hypoxia-regulated enzyme G6PDH was determine  for 
comparison. Renal G6PDH activities were increased in the salt-sensitive Dahl SS/Jr rats 
kept on highest NaCl intake level (6.50% w/w NaCl), whereas in salt-resistant Dahl SR/Jr 
rats any significant effect after variation of NaCl intake levels was not found (Table 5). 
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5.3 inhibition of nitric oxide synthase (study ii)
NOS inhibition by L-NAME upregulated the renal XO, XDH and XOR activities from 
10% up to 36% depending on the amount of NaCl in the diet (Table 6). Increases in 
renal XDH following different levels of NaCl were dose-dependent in SHRs both in the 
presence and in the absence of the L-NAME treatment. No dose-related effects were found 
between the level of NaCl intake and renal XO activity (Study II).
Long-term L-NAME treatment increased SBP markedly, approximately by 50 mm Hg. 
Dietary salt did not produce any significant or dose-response effect on blood pressure on 
groups treated with or without L-NAME (Study II).
L-NAME slightly increased renal G6PDH activities in groups kept on high NaCl diet 
(Table 6), whereas ALDH and LDH activities remained the same, or tended to be lower in 
L-NAME treated groups (previously unpublished results).
NOS inhibition increased circulating arginine levels at low NaCl intake levels (Figure 
10). At 1.1% of NaCl in the diet NOS inhibition did not have any effect. However, at 
the high level (6.2%), NOS inhibition decreased circulating arginine levels (previously 
unpublished results).
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Table 5. Renal activities of selected enzymes of salt-sensitive (Dahl SS/Jr)  and salt-resistant (Dahl 
SR/Jr) rats (Study I) kept on different NaCl intake levels (Panel 6B) NS, not significant; * p< 0.05. 
(unpublished data relating to Study I). 
NaCl%  
(w/w diet) 
N G6PDH (mU/g) LDH (mU/g) ALDH (mU/g) 
Dahl SR/Jr  
0.20 4 8.47 ± 0.56 0.47 ± 0.05 2.74 ± 0.80 
6.50 4 9.11 ± 0.15  0.43 ± 0.03 3.45 ± 1.08 
     
Dahl SS/Jr  
0.05 3 9.34 ± 0.38  0.45 ± 0.02 3.32 ± 0.96 
3.25 5 9.25 ± 0.25  0.44 ± 0.02 2.50 ± 0.09 
6.50 6 15.50 ± 1.71* 0.55 ± 0.03 4.20 ± 0.75 
     
ANOVA     
Dietary NaCl  p<0.001 NS NS 
Strain  p<0.01 NS NS 
 
 
5.3 Inhibition of nitric oxide synthase (Study II) 
NOS inhibition by L-NAME upregulated the renal XO, XDH and XOR activities from 
10% up to 36% depending on the amount of NaCl in the diet (Table 6). Increases in renal 
XDH following different levels of NaCl were dose-dependent in SHRs both in the 
presence and in the absence of the L-NAME treatment. No dose-related effects were found 
between the level of NaCl intake and renal XO activity (Study II). 
Long-term L-NAME treatment increased SBP markedly, approximately by 50 mm Hg. 
Dietary salt did not produce any significant or dose-response effect on blood pressure on 
groups treated with or without L-NAME (Study II). 
-  slightly increased renal G6PDH activities in in groups kept on high NaCl 
diet (Table 6), whereas ALDH and LDH activiti s remained the same, or tended to be 
lower in L-NAME treated groups (previously unpubl shed results). 
NOS inhibition increased circulating arginin  levels t low NaCl intake levels (Figure 
10). At 1.1% of NaCl in the diet NOS inhibition did not have any effect. However, at the 
high level (6.2%), NOS inhibition decreased circulating arginine levels (previously 
unpublished results). 
Table 6. Renal activity of XO, XDH and G6PDH in SHRs kept on different NaCl diet with or 
without NOS inhibitor L-NAME (Study II). *, p<0.05.(Study II) 
Table 5. Renal activities of selected enzymes of salt-sensitive (Dahl SS/Jr) and  
salt-resistant (Dahl SR/Jr) rats (Study I) kept on different NaCl intake levels (Panel 6B) NS,  
not significant; * p< 0.05. (unpublished data relating to Study I).
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Figure 10. Effect of unspecific NOS inhibition with L-NAME on circulating arginine levels in 
SHRs, kept three weeks on different salt intake levels (N=7–9 per group). The percentages refer to 
percents of NaCl in the diet (w/w) *, p<0.05 vs control group receiving the same amount of NaCl 
(Laakso, Vaskonen, unpublished data).
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Figure 10. Effect of unspecific NOS inhibition with L-NAME on circulating arginine levels in 
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Table 6. Renal activity of XO, XDH and G6PDH in SHRs kept on different  
NaCl diet with or without NOS inhibitor L-NAME (Study II). *, p<0.05.(Study II)
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5.4 increased nitric oxide availability (study ii)
The NaCl induced SBP was attenuated by IS-5-MN administration (Study II). In spite of a 
decrease in blood pressure, and the relatively long duration of the experiment (eight weeks), 
renal XO, XDH or XOR activities did not markedly change in the groups treated with 
IS-5-MN. Different NaCl intakes did not affect renal XOR activity. IS-5-MN treatment 
was found to alleviate NaCl-induced increase in SBP, but it did not produce any further 
decrease in SBP in the animals kept on the low NaCl diet. Renal G6PDH activities ranged 
from 16.3 to 19.3 mU/g, with no significant differences or tendencies. Renal ALDH ranged 
from 4.6 to 5.3 mU/g in low and high NaCl groups without IS-5-MN, respectively. The 
low NaCl group with IS-5-MN treatment had mean renal ALDH activity 6.0 ± 1.5 mU/
g, whereas the group receiving IS-5-MN treatment with high NaCl diet had renal activity 
4.3 ± 0.5 mU/g. None of the differences in these enzyme activities including LDH were 
statistically significant.
5.5 xor inhibition during development  
5.5 of hypertension (study iii)
Allopurinol (eight weeks, 10–21 mg/kg bw per day) did not alleviate hypertension. 
SHR groups with allopurinol tended to have lower blood pressure than groups without 
allopurinol (p<0.05 in ANOVA). WKY rats kept on the high NaCl diet with allopurinol 
had approximately 10 mm Hg lower SBP levels compared with WKY rats on the same diet, 
but without allopurinol (p<0.05).
The weight gain of SHRs kept on high NaCl was lower than SHRs on low NaCl 
diet despite of the similar food intake rate. In order to obtain unbiased relative renal and 
cardiac weight data, regression equations beween body weight and cardiac weight and 
between body weight and renal weight, were first established using all age groups of SHRs 
kept on low NaCl diet. Renal and cardiac weights were then calculated for all SHRs as 
residuals with respect to the corresponding regression line. Residuals are depicted in Figure 
9 and indicate that the allopurinol treatment prevented NaCl-induced renal and cardiac 
hypertrophy (p<0.05).
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Figure 9. Differences of organ weights of 13-week old SHRs kept on low (0.3% w /w) or  
high (6% w/w) NaCl diet with or without allopurinol (AP) in comparison with organ weight 
development of SHRs kept on the low NaCl diet. A highly significant linear correlation  
between body weight and renal (r=0.85, p<0.001) and left-ventricular weight (r=0.87, p<0.001) 
were obtained by regression analysis using SHR data from all age groups kept on low NaCl diet. 
The difference in organ weight residuals between the observed value of renal weight or left  
ventricular weight, and the corresponding expected values obtained from the regression equations 
were then used to produce the graph. *, p<0.05 (Study III). Reproduced with permission.
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5.6 zucker fa/fa model (study iv)
Initially, Zucker fa/fa rats had significantly higher body weight (mean 547  g) than the 
lean Zucker rats (mean 390 g). During the 10 month experiment Zucker fa/fa gained 
substantially more weight than the lean control rats (mean value of 770–814 g for obese 
Zucker fa/fa groups compared with mean of 550 g in the lean controls). Weight gain in 
Zucker fa/fa was similar regardless of diet.
Obese Zucker rats had nearly twice as high renal XDH and XO activities than lean 
Zucker rats (Figure 11). In spite of this, renal XDH mRNA levels did not show strain-
related differences. In the liver the differences in XDH and XO activities were much lower. 
Also hepatic mRNA levels did not differ between lean and obese rats on the control diet.
Ang II receptor blockage by valsartan was not found to have any significant effects 
on weight gain, plasma glucose or cholesterol levels, whereas plasma triglyceride levels 
were significantly decreased. SBP was increased in obese Zucker fa/fa rats during the 
experiment reaching 149.1 ± 5.0 mm Hg in the controls. In the valsartan treated group SBP 
was slowly changed throughout the course of the experiment and was only towards the 
end significantly lower than in the obese control group. Liver weight (normalised with the 
length of tibia) was higher in obese animals than in lean animals. Surprisingly, the valsartan 
group had the largest livers.
Valsartan decreased SBP by approximately by 20 mm Hg. Hepatic XOR was markedly 
decreased by chronic valsartan administration from 144 mU/g to 38 mU/g. The mRNA 
levels remained unchanged in the liver and in the kidney. The effect of valsartan on 
renal enzyme activities was less pronounced, approximately 15%, but the difference was 
marked between the lean and obese groups (Figure 11). No change was observed in the 
XO/XDH ratio.
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Figure 11. Renal (panel A) and hepatic (panel B) XDH, XO and XOR activities of lean  
and obese Zucker rats kept 10 months on standard diet with or without valsartan and on the  
atherogenic diet containing 6% w/w NaCl and butter. #, p<0.05 between lean and obese 
substrains; *, p<0.05 in comparison with obese controls. #, p<0.05 strain-related difference  
in rats kept on control diet. C-Lean, lean Zucker rats on control diet; C-Ob, obese Zucker  
fa/fa group on control diet; Val-Ob, obese Zucker fa/fa on control diet with valsartan  
and ADG-Ob, obese Zucker fa/fa on atherogenic diet.
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containing 6% w/w NaCl and butter. #, p<0.05 between lean and obese substrains; *, p<0.05 in 
comparison with obese controls. #,p<0.05 strain-related difference in rats kept on control diet. C-
Lean, lean Zucker rats on control diet; C-Ob, obese Zucker fa/fa group on control diet; Val-Ob, 
obese Zucker fa/fa on control diet with valsartan and ADG-Ob, obese Zucker fa/fa on atherogenic 
diet. 
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5.7 effects of cyclosporine
Effects of CsA on renal XDH and XO are presented. As depicted in Figure 12, CsA 
substantially increased renal XO activity, whereas XDH activity remained unchanged. 
XOR activities were lower in CsA experiment in comparison with other SHR studies 
presented, mean value for total XOR activity in the control rats kept on low NaCl diet was 
16.6 mU/g.
Results relating to the effects of CsA on renal function and blood pressure have been 
previously published separately (Mervaala et al., 1997) and will be referred to only in the 
discussion part of the present study.
Figure 12. Effects of nephrotoxic doses of cyclosporine (CsA) on renal XDH and XO  
in SHRs. Controls were kept on standard laboratory chow. NaCl refers to a diet containing  
6.6% NaCl (w/w) and Mg to a diet containing the same amount of NaCl (6.6% w/w) with the 
addition of 0.8% Mg2+ (as MgCl2). Each group consisted of 7–8 rats. These data show that the 
activity of potentially ROS generating XO isoform was markedly upregulated in CsA induced 
nephropathy and furthermore modified by dietary NaCl, while renal XDH remained unchanged. 
*, p<0.05 in comparison with respective control. Unpublished data (Laakso, Pere,  
Mervaala and Lapatto). The experimental setting with functional and histopathological  
data has been previously published in detail (Mervaala et al., 1997).
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5.8 summary of findings
The main findings of the studies are presented in Table 7. Strain related upregulation 
of renal XDH and XO and specific mRNA was found in one obese rat strain and two 
rat strains having a predisposition to hypertension. Only slight strain-related changes 
were found in the heart and in the liver. Increased dietary NaCl induced hypertension 
and resulted in renal and cardiac hypertrophy in hypertension-prone rats. This was also 
observed to a much lesser extent in hypertension resistant rats. In salt-sensitive Dahl SS/Jr 
XOR induction with dietary NaCl was accompanied with upregulation of renal G6PDH 
activity. LDH remained unchanged. Concomitantly with increases in blood pressure, there 
was an upregulation of renal XDH and XO activities, and specific mRNA. Allopurinol 
completely inhibited XOR activity in vivo. XOR inhibition was not accompanied with 
any decrease in blood pressure levels in salt-sensitive SHRs, whereas in WKY controls a 
slight, but significant decrease was noted. In spite of the lack of effects on blood pressure, 
allopurinol prevented development of cardiac and renal hypertrophy.
NOS inhibition induced malignant hypertension, LVH, and renal hypertrophy. In 
the kidney, XOR activity was upregulated in L-NAME treated rats. In this relatively 
short experiment with L-NAME treated rats, increasing dietary salt did not aggravate 
hypertension. Increased levels of dietary NaCl did not induce renal XOR activity. NaCl 
loading decreased circulating arginine levels in L-NAME treated rats. Renal G6PDH was 
slightly increased. NO donor IS-5-MN alleviated hypertension without any effects on 
renal XOR.
Nephrotoxic CsA doses resulted in substantial upregulation of the XO isoform only. 
XO activity was increased further by increasing dietary NaCl intake.
At the end of the 10 month experiment, XOR activities were increased in kidneys 
and liver of obese Zucker fa/fa rats compared with lean controls. The atherogenic diet 
did not aggravate obesity or increase blood pressure. Administration of Ang II receptor 
blocker valsartan, markedly decreased hepatic XOR activity, and to a lesser extent, also 
renal XOR. In contrast to hypertension-prone rat, in obese Zucker fa/fa rat the changes 
in XOR activity were derived from post-translational modification, since specific mRNA 
remained unchanged.
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Table 7. Summary of the findings related to XOR induction in the present series of studies
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6 Discussion
6.1 methodological aspects
6.1.1 Animal models of essential hypertension and metabolic syndrome
While hypertension involves complex genetic and environmental factors in human 
populations, well-defined animal models in controlled experimental settings provide a 
possibility for experimentation and have greatly increased the understanding of underlying 
factors in cardiovascular diseases. Several genetic models of hypertension have been 
generated. However, none of the models reflects all of the mechanisms underlying essential 
hypertension or metabolic syndrome.
Inbred rat strains, such as SHR, have been developed by selective mating of normotensive 
WKY rats for 20 generations or more in order to obtain the hypertensive phenotype. SHRs 
begin to generate hypertension at approximately five weeks of age. The selection procedure 
did not involve dietary manipulation. SHR is by far the most used experimental rodent 
model corresponding to approximately 30% of publications found with the keywords 
‘rat, hypertension’. Another inbred strain, hypertension-prone Dahl SS/Jr and its control, 
salt-resistant Dahl SR/Jr has been established by selection on the basis of differences in 
blood pressure after challenging with a diet containing 8% (w/w) NaCl. In these models 
the hypertension trait results from a number of genes. Breeding protocols have produced 
several rat strains, in which blood pressure increases in a reproducible manner. The models 
show complex genetic background and in that resemble human essential hypertension 
(Rapp, 2000).
The molecular basis of essential hypertension is polygenic and has remained unresolved. 
The inbred hypertension- and obesity-prone rat models have different genetic determinants, 
which interact with dietary factors. Particularly Dahl SS rats and SHRs have been used to 
identify quantitative trait loci (QTL), i.e. areas of DNA in chromosomes, which associate 
with the phenotype (Aneas et al., 2009, Mattson et al., 2008). The hypertensive phenotype 
comprises of relevant features, such as salt-sensitivity, spontaneous hypertension, insulin 
resistance, proteinuria etc. Once a promising loci has been found, the respective chromosome 
(or the area of DNA) can be transferred to a recipient strain to produce chromosomic 
substituent strains (consomic strains). The identified QTLs have been divided in to loci, 
which are associated with salt-sensitivity, to loci which affect the phenotype regardless of the 
salt intake or have influence only at a ‘normal’ salt intake level (Aneas et al., 2009).
There are also surgical models, such as the Goldblatt model, in which, following the 
removal of one of the kidneys, the renal artery of the remaining kidney is constricted. 
Kidney removal is not a prerequisite, and there are several variations of the model. These 
invasive models mimic renal disease, and have been used in short-term mechanistic studies 
(Pinto et al. 1998).
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Numerous pharmacological models exist, such as the DOCA-NaCl model, described 
earlier, as well as models based on the inhibition of NO production (Ribeiro et al., 1992) or 
inhibition of urate elimination (Mazzali et al., 2002). Several genetically modified rats have 
been developed, which specifically target one or a few factors involved in the development 
of hypertension. Double transgenic rat expressing the human renin and angiotensinogen 
gene, described by Ganten et al. (1992) is one of such approaches. As compared with inbred 
rodent models of essential hypertension, both pharmacological and transgenic models have 
features relating to secondary forms of hypertension.
The obese Zucker fa/fa rat is a prediabetic model of metabolic syndrome, which 
has a predisposition for development of mild hypertension and develops at a lower rate 
than in SHRs or Dahl SS/Jr rats. The Zucker fa/fa rat is originated from a spontaneous 
mutation (Zucker, 1965), which was later localized in the leptin receptor gene. The 
phenotype is characterized by hyperphagia, hyperlipidemia and mild glucose intolerance 
(Speakman et al., 2008). While the obese Zucker rat has been demonstrated to have only 
one mutation resulting in obesity, there are also several polygenic models of metabolic 
syndrome, such as Goto-Kagizaki rat. Evidence has accrued that obesity is a complex 
and heterogenic state.
The salt-sensitivity of obese Zucker fa/fa rat has been a controversial subject. According 
to Reddy and Kotchen (1992) Zucker rats are salt-sensitive in comparison with genetically 
close lean controls, whereas Pawloski et al. (1992) demonstrate that obese Zucker rats are 
normotensive regardless of the NaCl content in the diet. In these models, salt-sensitivity 
has been associated with hyperglycemia (Carlson et al., 2000). In the present studies serum 
glucose levels of obese Zucker fa/fa rats did not differ from lean Zucker rats and the rats 
were not salt-sensitive (Study IV).
In the rat and in most other mammals urate is metabolized by uricase in the liver to 
allantoin, while the kidneys do not express the enzyme (Watanabe et al. 2002). None of 
the species generally used to model hypertension are uricotelic. On the other hand the 
situation allows to study local effects of urate production. For studies on XOR, generation 
of urate is only one of features, which may relate to cardiovascular phenomena.
6.1.2 Dietary modifications
The NaCl intake in present studies varied were typically from 0.2 to 6.6% (w/w) in the 
diet. Such levels are commonly used in rodent models of hypertension. 
Typically, a basic commercial rodent diet contains 0.275 g of Na+ / 100 g of the diet, 
i.e. in relation to energy content of the diet 0.22 g/MJ as Na+, i.e. 0.54 g NaCl /MJ. This 
level is relatively close to the current recommendation policy for intake level for non-obese 
humans, 6–7 g/d, i.e. approximately 0.5 g/MJ. In relation to energy intake, the low intake 
of NaCl in the present rodent studies was close to dietary recommendations for humans by 
WHO (Nishida et al., 2004).
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The lowest dietary level of NaCl investigated (Study I) was 0.05% (w/w) and clearly 
deficient, since weight gain in both salt sensitive and resistant rats was substantially decreased, 
whereas 0.20% (w/w) dietary NaCl resulted in the approximately same weight gain as from 
higher NaCl levels. Modifying the diet with NaCl did not influence palatability as judged 
from food intake levels (data not shown).
6.1.3 Biochemical methods 
Several methods can be used to determine XO and XDH activity. Some of the methods 
use artificial substrates and the others rely upon endogenous substrates. Whereas highly 
sophisticated studies have been published describing mechanisms of XOR catalyzed reac-
tions, no systematic studies are available describing the substrate preferences of all XOR 
isoforms.
In the Studies I, II and III, the conversion of pterin to a fluorescent product 
isoxanthopterin was used. In the Study IV radiolabeled xanthine was used as a substrate 
and the formation of radioactive urate was determined with a radiodetector after HPLC 
separation. As indicated in Section 2.9 supra, XOR proteins can have different activities. 
XOR participates in pterin metabolism and both reactions are physiological.
Some of the published assays use artificial substrates, such as 2,6- dichlorophenolindo-
phenol, which can be determined by UV spectroscopy. Determination of fluorescent prod-
uct, resorufin, which is formed by XO catalyzed O 2 
-  generation from Amplex Red, has also 
been used. Furthermore, discoloration of methylene blue to determine total XOR has been 
employed. Intercalibration studies of the various methods have been scarce.
6.2 NaCl-induced blood pressure and renal  
6.2 and cardiac hypertrophy
In salt-sensitive rats, intake levels at or exceeding 3.25% NaCl (w/w) in the diet resulted 
in sustained increase of systolic blood pressure levels reaching 200 mmHg or more. 
Such malignant hypertension results in target organ changes and damage, including 
left ventricular hypertrophy and renal enlargement as observed in Studies I and II, an 
effect, which is well-established in the literature (Mervaala et al., 1992 and Mervaala et 
al., 1994b).
Histological examinations were not carried out in the present set of studies. Previous 
reports have shown that NaCl -induced renal growth is due mainly to renal hypertrophia 
in Dahl SS/Jr rats (McCormick et al., 1989).
In the Study I, a significant correlation was found between relative kidney weight 
and renal XOR activity in Dahl SS/Jr but not in Dahl SR/Jr rats. In pathological renal 
enlargement, the diffusion distances for oxygen may be increased and limit oxygen 
availability in the most susceptible areas.
68
An atherogenic diet, containing a high NaCl level and butter, increased blood pressure 
only modestly in obese Zucker fa/fa rats in comparison with rats kept on control diet 
(Study IV). Liver weights (adjusted to tibia length) were higher in obese Zucker fa/fa rats 
in comparison with the lean controls.
6.3 strain-related differences in renal xor activity
The findings (Studies I and II) of increased kidney XOR activities in two different rat 
models of hypertension, namely the Dahl salt-sensitive model and the SHR model, may 
reflect the intrinsic metabolic differences between these strains and associate with the 
hypertensive trait.
In agreement with our findings, Delano et al. (2006) found upregulated XOR and 
NAD(P)H oxidase levels in SHR in several cell types including leucocytes, arterial, and 
venous endothelium, by using specific antibodies and horseradish peroxidase staining.
Salt-sensitivity of obese Zucker fa/fa rats has been a controversial subject (Fujiwara et 
al., 1999). In contrast to SHRs, only the XOR activities were increased in Zucker fa/fa 
rats on the control diet, whereas specific XDH mRNA levels remained unaltered. In obese 
Zucker fa/fa rats (Study IV), also hepatic XOR activity was elevated to some extent and 
again, without effects on XDH expression.
6.4 NaCl intake and renal xor activity
A dose-dependent induction of XOR was found in response to increases in salt intake in 
salt-sensitive rats in contrast to salt-resistant rat strains. Literature searches demonstrate 
that Study I is the first report on the effects of dietary salt on renal XOR activities. Two salt-
sensitive rat strains Dahl SS/Jr and SHR and their respective genetic controls Dahl SR/Jr 
and WKY were used. Furthermore, the effects were seen only in the kidney of hypertension-
prone salt-sensitive rat strains, and not in the heart.
In both Dahl SS/Jr and Dahl SR/Jr control strain, renal XOR activities were markedly 
decreased when the rats were kept on NaCl deficient diet, and did not show any effect 
on blood pressure compared with low NaCl intake levels (0.08% w/w Na+). This result 
indicates that renal XOR activity is, at least at low NaCl intake levels, associated with renal 
sodium and possibly with chloride handling.
In humans, high circulating urate levels have been proposed as one of the means to 
maintain blood pressure during salt restriction. This ability of high urate levels has been 
claimed as one of the evolutionary benefits obtained in humans and great apes, when the 
ability to degrade urate was silenced due to mutations in the uricase gene. This hypothesis 
was put forward by Johnson et al. (2008), when it was found that inhibition of uricase 
by oxonic acid in rats results in the development of salt-sensitive hypertension. In the 
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present study, rats fed with deficient NaCl levels resulted in growth retardation, and did 
not upregulate XOR, but on the contrary XOR activity was substantially decreased in both 
salt-sensitive and salt-resistant rats as a response to NaCl restriction. The result indicates 
that XOR activity is not regulated as to increase urate production during NaCl restriction, 
but rather, to decrease it.
There are not many studies addressing the effects of dietary salt intake on XOR activity 
or expression. Lenda and Boegehold (2002) reported that both XOR and NADPH oxidase 
activities and expression were unchanged in skeletal muscle microcirculation of Spraque-
Dawley rats kept for 4–5 weeks on a diet containing either low or high amounts of NaCl. 
In spite of the lack of response in enzyme activities, the authors found an increase in ROS 
generation in the microvessels, which was inhitable by oxopurinol and DPI.
In the present studies renal XOR activities correlated with renal weight to body weight 
ratios, which may indicate that renal XOR induction is a consequence of hypertension and 
subsequent renal damage. Statistically, kidney XDH and XOR activities revealed a close 
correlation with systolic blood pressure in both the Dahl SS/Jr and SHR.
Systolic blood pressure of Dahl SS/Jr rats kept on standard NaCl diet (0.20% w/w) 
did not differ from the group kept on the NaCl deficient diet. Renal XOR activity was 
decreased substantially in the NaCl deficient group, indicating that blood pressure is not 
the only factor contributing to changes in renal XOR activity.
In obese Zucker rats (Study IV), blocking the angiotensin receptor with valsartan 
decreased both renal XOR activity as well as XOR expression at the mRNA level, which 
indicates that XOR regulation is related to angiotensin II levels or its effects on blood 
pressure, or both.
6.5 nitric oxide and xor
6.5.1 Inhibition of nitric oxide synthesis
In the present study (Study II), unselective NOS inhibition by L-NAME was found 
to produce a modest upregulation of renal XOR activity. In this experimental setting, 
increasing the intake of NaCl increased renal XOR activity in L-NAME treated SHRs. 
Inhibition of NOS activity by L-NAME has been previously reported to increase the oxygen 
cost of NaCl transport in Wistar rats (Deng et al., 2005). Unselective NOS inhibition 
has demonstrated to increase oxygen consumption by several mechanisms including an 
increase in mitochondrial metabolism. A relatively high daily L-NAME dose was used, 20 
mg/kg, which was reported to produce not only malignant hypertension but also cardiac 
infarcts in all test animals (Vaskonen et al., 1997).
In the present study, NOS inhibition increased SBP regardless of the NaCl intake 
level. Administration of a low dose of L-NAME, which is not sufficient to increase blood 
pressure, has been shown to render salt-resistant animals to salt-sensitive (Salazar et al., 
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1993). Increased level of dietary salt aggravates the target organ damage caused by L-
NAME treatment leading to high occurrence of stroke (Vaskonen et al., 1997). In the 
present study, NaCl-induced changes, with or without NOS inhibition, in renal XOR 
activity were rather small, which may relate to the relatively short duration (three weeks) 
of the experiment.
The present study also indicated that circulating arginine levels are decreased along with 
increasing NaCl-intake in the L-NAME treated SHRs, but not in the controls. Kitiyakara 
et al. (2001) also found higher circulating arginine levels in Sprague-Dawley rats kept on 
low NaCl intake. Arginine is synthesized endogenously mainly in renal tubules (Lim et 
al., 2007). While arginine may be spared by NOS inhibition, the present study may also 
indicate that there is a concomitant upregulation of arginase (EC 3.5.3.1) acitivity. In 
cell cultures and also in vitro, L-NAME has been shown to inhibit arginase (Reisser et al., 
2002). Recent studies suggest that the mitochondrial arginase isoform II regulates NO 
production in the endothelium (Lim et al., 2007). Arginase inhibition has been shown 
to alleviate development of hypertension in SHRs but not hypertension-induced cardiac 
hypertrophy (Bagnost et al., 2008).
Together, the results from Study II and the current literature indicate that NOS 
inhibition by L-NAME may modify NO production by several effects on arginine 
metabolism and, furthermore, these effects are modified by dietary salt intake. The L-
NAME treated SHR is a high-renin model of hypertension (Vaskonen et al., 1997). In 
addition to its guanylate cyclase mediated vasodilatator effects, NO is a powerful regulator 
of cellular oxygen consumption (Victor et al., 2007). NO deficiency may impair oxygen 
distribution and subsequently result in XOR induction.
6.5.2 Treatment with a nitric oxide donor
The nitric oxide donor, IS-5-MN, significantly reduced salt-induced hypertension. The 
rats treated with IS-5-MN were still hypertensive and sensitive to dietary NaCl. IS-5-MN 
treatment did not have any effects on renal XOR activity. These results are in line with 
previous studies indicating that endothelial NO production is upregulated in SHR before 
and after the onset of hypertension (Vaziri et al., 1998).
Organic nitrates are important antianginal vasodilatating drugs introduced more than 
one hundred years ago. Prolonged therapy with organic nitrates is associated with loss of 
efficacy. These drugs can be considered as prodrugs, since many of their effects have been 
attributed to release of NO. Chen et al. (2002) have shown that aldehyde dehydrogenases 
(ALDH1 and more notably the mitochondrial isoform, ALDH2) metabolize glycerol 
trinitrate (GTN) to nitrate, whereas IS-5-MN and its dinitrated congener IS-5-DN, are 
not at all metabolized by ALDH. Both cytosolic (ALDH1) and mitochondrial ALDH2 
convert GTN to nitrite (Beretta et al., 2008), which can then be converted to NO by XOR. 
In the present study, dietary NaCl increased total ALDH activity and in theory would 
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therefore not reduce the efficacy of reactive organic nitrates, such as GTN. Furthermore, 
the present study also indicates that NO derived from IS-5-MN does not downregulate 
ALDH in vivo. The enzyme which activates IS-5-MN has not been identified.
6.6 renal xor induction by cyclosporine
CsA is an immunosuppressive drug used in organ transplantation. CsA use is plagued by 
its acute and chronic nephrotoxic effects. Dietary NaCl has been reported to aggravate 
CsA induced nephrotoxicity in rats (Pere et al., 2000). CsA nephrotoxicity is associated 
with fibrosis, hypertension, renal vasoconstriction, subsequent renal hypoxia, as well as 
increased angiotensin II and aldosterone activity resulting in potentially irreversible renal 
dysfunction (Bobadilla and Gamba, 2007).
Results relating to effects of CsA on renal function and SBP have been previously 
published separately (Mervaala et al., 1997), where CsA produced malignant hypertension, 
which was aggravated by increase in dietary NaCl. The combined CsA/high NaCl diet was 
accompanied with up to a sevenfold increase in the amount of protein excreted in urine. 
Magnesium supplementation decreased blood pressure levels and proteinuria in groups 
treated with CsA and kept on high NaCl diet. It is also noteworthy that the same CsA 
treated rats had twice as high plasma renin activity than controls kept on the low NaCl diet 
(Mervaala et al., 1997).
In the present study, CsA was found to induce the activity of renal XO while renal 
XDH remained unchanged. XO induction was alleviated by magnesium supplementation 
and exacerbated by increased NaCl intake. These results parallel with previously published 
CsA induced renal dysfunction and histological changes (Mervaala et al., 1997).
Studies on Wistar-Kyoto rats have reported that allopurinol markedly alleviates CsA 
induced hypertension (Kobelt et al., 2002). In their study Kobelt and coworkers (2002) used 
an oral CsA dose at 8 mg/kg body weight/d and allopurinol at 50 mg/kg body weight/d. 
Furthermore, the authors found that CsA decreased renal plasma flow, which was markedly 
improved by allopurinol. CsA has been reported by Mazzali et al. (2001b) to increase uric 
acid levels in rats. Increasing urate levels using oxonic acid to inhibit uricase exacerbates 
CsA nephrotoxicity (Mazzali et al., 2001b). These observations are in line with the present 
data, which indicate that the activity of the urate producing enzyme XO is upregulated by 
high NaCl intake and that CsA further increases the enzyme activity.
MgCl2 has been found to alleviate CsA toxicity ((Mervaala et al., 1997), and in the 
present study it decreased NaCl and CsA induced XO activity. Used alone MgCl2 was 
found to induce XO in a similar fashion as NaCl, an effect, which may relate to independent 
influence of chloride ion as discussed supra in Section 2.3.1. MgCl2 supplementation has 
been considered beneficial in experimental studies on the harmful effects of dietary NaCl 
(Mervaala et al., 1992).
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It is possible that XO induction by CsA is the result from direct cellular toxic effects 
of CsA. It is interesting to note that in rat pulmonary endothelial cell cultures, tobacco 
smoke condensate has been reported to induce XOR (Kayyali et al., 2003), indicating 
that XOR induction could be part of a pre-programmed general cellular response to 
toxic compounds. Many hepatotoxic compounds, such as halothane and ethanol, has 
been reported to increase the release of XOR from the liver into the circulation (Pacher 
et al. 2006).
The present study demonstrated that CsA is able to upregulate only the XO isoform. 
XO has been associated with ROS production and subsequent tissue damage in I/R 
(McCord, 1985). In Fischer rats, a few days after kidney transplantation, renal XOR activity 
has been reported to substantially increase in allografts, up to levels 15 times higher than 
in controls, whereas in syngrafts no change was observed (Sun et al., 2004). The study 
indicates that XOR may also have a role relating to the survival of the transplant. Present 
data on induction of XO by CsA justify further studies on feasibility of XOR inhibition to 
improve allograft survival and to avoid CsA toxicity.
6.7 xor and metabolic syndrome
In the present studies XOR activity was not only found to be upregulated in hypertension-
prone rats, but also in rats with a predisposition to obesity, i.e. Zucker fa/fa rats. 
Administration of valsartan, an AT1 receptor blocking agent, did not lower body weight 
and did not have any effect on circulating cholesterol levels. Valsartan is not an agonist of 
the nuclear receptor, peroxisome proliferator-activated receptor- (PPAR). In this respect 
it differs from telmisartan (Sugimoto et al. 2006) Recently, Cheung et al. (2007) reported 
that XOR +/- knock-out mouse had 50% reduction in adipose mass. In the same study it 
was also found that XOR is a regulator of PPAR in 3T3-Li adipose cell cultures.
In the present study, chronic administration of valsartan decreased hepatic XOR activity 
substantially, but did not have any effects on XOR at mRNA level. In the kidney valsartan 
had a less pronounced effect on renal XOR activity and showed no effects on specific 
mRNA levels. In spite of the downregulation of XOR activity any reduction in weight gain 
was not found in the valsartan treated group. Interestingly, valsartan reduced hepatic and 
renal XOR activities in obese Zucker rats, pointing towards that hepatic XOR is regulated 
by Ang II. There is evidence that urate in turn can regulate intracellular Ang II levels 
(Corry et al., 2008) revealing a possibility of positive feed-back loop.
There is evidence indicating that hepatic effects of Ang II receptor blockers are mediated 
through upregulation of Ang 1–7 rather than inhibition of Ang II receptor AT1 (for review, 
see Lubel et al., 2008). With respect to metabolic syndrome, there has been more interest 
on cardiovascular than hepatic effects of Ang II receptor blockers.
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6.8 inhibition of xor activity
Allopurinol is an established urate lowering agent and a specific inhibitor of XOR (reviewed 
by Pacher et al., 2006). XOR and AO convert allopurinol to the even more potent XOR 
inhibitor oxypurinol. Allopurinol is not an inhibitor of aldehyde oxidase and has a 
short half-life, 2.5 hours, in contrast to 15 hours of oxypurinol. It does, however, have 
greater bioavailability than oxypurinol and as such was therefore chosen for the present 
experiments. While both compounds inhibit urate production, there is evidence indicating 
that the inhibited enzyme may still transfer electron to oxygen and thus produce ROS 
(Myamoto et al. 1996). This may partly explain some of the controversial results.
To avoid toxic side-effects and nonspecific effects of the drug, the lowest possible 
allopurinol dose level was chosen, but at a level that still completely inhibited XOR activity.
In the present study Allopurinol did not have any significant effects on blood pressure. 
In contrast to the present findings, a randomized, double-blind, placebo-controlled clinical 
study with allopurinol has recently been carried out by Feig and Soletsky (2008) who 
found that allopurinol can decrease blood pressure in humans.
Allopurinol has later been shown to decrease blood pressure, if urate degradation by the 
uricase enzyme has been inhibited by oxonic acid (Mazzali et al., 2001a).
Most, but not all experimental studies using allopurinol or oxopurinol, have had a 
positive outcome with regard to cardiac parameters. It is not known whether these effects 
can be attributed to effects of allopurinol on XOR or to effects on other pathways.
On the other hand, a recent study with the Dahl SS/Jr strain demonstrated, in line with 
this study, that allopurinol did not alleviate the salt-induced development of hypertension. 
In agreement with this result allopurinol was reported not to improve renal function 
(Tian et al., 2008).
6.9 xdh to xo conversion
The conversion from XDH to XO has been proposed to be important in the pathogenesis 
of reperfusion induced tissue injury. It has been postulated that during prolonged ischemia, 
XDH to XO conversion is increased. At the time when circulation and oxygen availability 
is re-established, XO produces harmful reactive oxygen species resulting in organ damage 
(McCord and Roy, 1982; McCord, 1985).
In the present work, the Dahl SS/Jr rats had higher XO/XOR ratios compared with the 
SHRs. The data have been derived from separate experiments, which may partly explain 
the difference. Sample handling may also affect XO/XOR ratios. Since the experiments 
were independently carried out direct comparison of the results was not possible.
CsA nephrotoxicity was discussed separately in the Section 6.6, but in this case a marked 
XDH to XO conversion took place, which presumable was protease mediated.
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6.10 hypoxia and renal xor
As hypoxia is a sufficient, but not unique signal for XOR induction, the finding of increased 
renal XOR in hypertensive rats is in line with the hypothesis of hypertension associated 
renal hypoxia. The first direct demonstration of renal hypoxia in hypertensive rat was made 
by Welch et al. (2001). Oxygen content in arterial and venous renal blood was measured 
in WKY rats and SHRs with an oximeter. The authors found an oxygen tension (pO2) 
of 40–50 mm Hg in the renal cortex, whereas in the medulla pO2 was only 10mm Hg. 
In the cortex, pO2 was found to be 10mm Hg lower in the SHRs than in WKY rats. The 
authors were also able to estimate that in relation to a given amount of Na+ transport, the 
corresponding renal oxygen cost is approximately 50% higher in hypertensive SHRs than 
in normotensive WKY rats. Li and co-workers (2003) have confirmed the previous findings 
of decreased oxygen levels in the SHR kidney by MRI techniques. Recent experimental 
studies have provided evidence that the lower renal oxygen tension in SHRs precedes the 
development of hypertension (Welch, 2006).
In cultures of human bronchial epithelial cells, normoxic oxygen levels have been 
reported to markedly suppress XOR activity. Linder et al. (2003) found that extremely low 
oxygen levels (0.5 – 3%) increased XOR activity by 300 – 800%. In cultured endothelial cells, 
low oxygen levels, comparable to those occurring clinically in modest arterial hypoxia (i.e. 
10% O2) increased XOR levels threefold (Kelley et al., 2006). In both studies, suppression 
of protein synthesis did not alter XOR activity. Contrary to cell culture studies, the present 
in vivo study (Study III) on SHRs demonstrated that not only XOR activities, but also 
renal XDH mRNA levels were increased. Hypoxia-induced synthesis of XOR protein has 
been found in cell lines of endothelial origin (Terada et al., 1997).
The activities of several enzymes, regulated by hypoxia and redox homeostasis, were 
studied. HIF-1 mediates upregulation of many enzymes involved in glycolysis. HIF-1α 
does not regulate XOR (Linder et al., 2003). LDH is an enzyme which usually shows one 
of the highest responses to hypoxia (Marti et al., 1994). G6PDH catalyzes the first and rate-
limiting step in pentose phosphate shunt, which generates reducing equivalents such as 
NAD(P)H, used for example by glutathione reductase to regenerate GSH from its oxidized 
form GSSG. GSH may then be used by glutathione peroxidase to degrade H2O2 into H2O 
and O2. As the pentose phosphate pathway spares oxygen, it is an important source of 
reducing equivalents, when oxygen tension is low (Bartrons et al., 2007).
The response of these enzymes in the present studies was variable. In Study II, NOS 
inhibition by L-NAME produced a small, but significant decrease in renal LDH, and 
a small increase in G6PDH activities in SHRs. In contrast to SHR data, in Dahl salt-
sensitive SS/Jr rats, renal G6PDH was significantly induced (up to 67%) at highest NaCl 
intake level (6.5% w/w), whereas, in salt-resistant Dahl rats, no response was obtained. 
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It is interesting to note that upregulation of G6PDH is associated with increased cell 
growth in cultures of fibroblasts (Tian et al., 1998). IS-5-MN did not exert any effect on 
renal G6PDH activities. These data point towards that NaCl-induced changes in glucose 
metabolism occurs in the Dahl SS/Jr kidney, while in SHR the response is blunted.
In contrast to SHR and Dahl models, increasing NaCl intake did not induce renal 
XOR in obese Zucker fa/fa rats. In this model dietary NaCl produced only modest increase 
in SBP. The Ang II receptor blocker, valsartan, resulted in an alleviation of blood pressure 
and only a slight decrease in renal XOR activity in obese Zucker fa/fa rats kept on low 
NaCl intake. These results point towards that Ang II upregulates XOR activity, but the 
effect is tissue specific.
6.11 clinical importance
As stated earlier, XOR has been detected in the human liver and the intestine. The low or 
undetectable cardiac activities decreased scientific interest in XOR inhibition as a means 
to treat cardiac dysfunction, but the interest in XOR has not totally declined. In a more 
recent electron spin resonance based studies by Spiekermann and co-workers (2003) 
demonstrated that a XO isoform is localized in human endothelium, from where it can be 
liberated with a bolus of heparin. The authors also found upregulation of XOR activity in 
the coronary arteries of patients with coronary disease along with another ROS producing 
enzyme, NAD(P)H oxidase.
While studies on rodent models have revealed some positive effects of XOR inhibition 
(Table 3), results from clinical studies have been controversial (Table 4). It can also be noted 
that even in studies with a positive outcome, it is not known, whether the effects can be 
attributed to XOR inhibition or to other possible effects of allopurinol and/or oxypurinol. 
Nearly all clinical studies so far have been based on surrogate endpoints and involved a 
small number of patients. In a recently reported OPT-CHF multicenter study, 405 patients 
with NYHA class III–IV congestive heart failure were recruited (Hare et al., 2008). In the 
study, oxypurinol was added to the best conventional therapy in a double blind setting. 
The clinical outcome was not improved in unselected patients, but statistically significant 
benefits in terms of mortality and need for emergency treatments or hospitalization were 
found in a subgroup selected on the basis of high urate levels. It was also noted that the 
use of oxypurinol in such a group is not without risk. Subgroup analysis revealed that the 
group experiencing harmful consequences was found to consist of patients, whose serum 
urate levels failed to decrease in response to oxypurinol therapy.
Whether XOR inhibition confers any advantage to allograft survival and possibilities 
to prevent or alleviate renal pathologies during immunosuppression is also controversial. 
In combination with an experimental study showing alleviation of CsA-induced renal 
dysfunction by allopurinol (Kobelt et al., 2002), the present findings of CsA induced XOR 
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upregulation indicates that XO is involved in CsA-induced renal effects. Human XOR 
activities have been studied after lung and heart transplantation involving CsA treatments 
(Kinnula et al., 1997). Any XOR activity or induction in the lung, heart or plasma was 
not detected by analysing the activity using radiolabeled 14C-xanthine as a substrate. The 
methods were fully functional as hepatic and intestinal XOR activities were significant.
The present experimental studies indicate that renal XOR is upregulated in hypertension 
and metabolic syndrome and also that dietary factors and antihypertensive drugs influence 
renal XOR. Inhibition of XOR did not decrease SBP. In salt-sensitive rats both renal and 
cardiac enlargement was prevented by allopurinol treatment. These effects were found 
in rats after chronic allopurinol treatment, which was started prior to development of 
hypertension. More experimental studies are needed to clarify these issues.
Further experimental studies would be needed to clarify the role of XOR in left 
ventricular hypertrophy, which is clinically one of the serious outcomes associated with 
essential hypertension.
6.12 future directions
Present studies showed that XOR inhibition does not have an effect on blood pressure, but 
is able to prevent cardiac and renal hypertrophy. Although the mechanisms are unclear, 
the latter finding may provide therapeutic possibilities. At present there are no specific 
inhibitors for XO and XDH or useful in vivo inhitors of XDH to XO conversion. Such 
compounds could be helpful to clarify the physiological and pathological role of different 
XOR catalyzed reactions by separating the generation of ROS from other catalytic activities. 
Such inhibitors could be tested for prevention of CsA induced toxicity during organ 
transplantation. They could also be used to clarify the physiological and pathophysiological 
roles, if any, of nitrate and nitrite reduction.
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7 Summary
Experimental studies were carried out to investigate the role of XOR in hypertension and 
metabolic syndrome. Renal and cardiac XDH and XO activity and expression of XDH 
mRNA was studied in hypertension-prone rats during the development of NaCl-induced 
hypertension. A specific XOR inhibitor, allopurinol was used to clarify whether XOR has 
any causal role in the development of hypertension. Pharmacological modifications of 
NO production and availability were used to study interrelationships between NO and 
XOR. Renal XOR was studied during CsA induced immunosuppression, as NaCl has been 
previously shown to aggravate CsA nephrotoxicity, resulting in malignant hypertension. 
Interrelationships between RAS and XOR in the kidney and the liver of obese rats were 
studied by inhibiting RAS with valsartan, an angiotensin II receptor blocker. With reference 
to the reviewed literature, XOR may have competing roles generating the powerful 
antioxidant urate on one hand and ROS and possibly NO on the other. 
The main outcomes are:
• Renal XOR is a marker of salt-sensitivity in rodent models of hypertension.  
All studied hypertension-prone, salt-sensitive rat strains had higher renal activity 
of XDH and XO than their genetically close normotensive control strains.
• Dietary NaCl dose-dependently induced renal XDH and XO activities in 
hypertension-prone, salt-sensitive rat strains with increasing intake of NaCl, 
whereas cardiac and hepatic XOR activity remained unchanged. Increased 
intake of NaCl did not alter renal XOR activities in salt-resistant strains. Renal 
XOR activity correlated with blood pressure levels and with cardiac and renal 
hypertrophy.
While renal XOR activity may be increased by several potential mechanisms, 
including angiotensin II, XOR upregulation is likely to result from salt-induced 
renal hypoxia in hypertension-prone rats. Upregulation of renal G6PDH in Dahl 
SS/Jr salt-sensitive rats also points towards NaCl-induced renal hypoxia. 
In the salt-sensitive rats, upregulation of renal XOR was accompanied with 
increased mRNA levels indicating that higher XOR activity in the salt-sensitive 
kidney derives from local protein translation rather than from binding of circulating 
XOR enzyme or post-translational modifications alone.
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• Decreasing NO production by NOS inhibition with L-NAME induced 
malignant hypertension and upregulated renal XDH and XO activities. Since L-
NAME is known to result in marked hemodynamic changes in renal circulation, 
its effect on renal XOR activity may also, at least partially, be attributed to 
changes in oxygen availability.
 NO surplus, derived from IS-5-MN administration, markedly alleviated 
salt-induced hypertension, but had only negligible effects on renal XOR activity 
indicating that in vivo XOR is not inhibited by NO.
• Induction of renal XDH and XO in SHRs do not precede the development 
of hypertension, but progress concomitantly with an increase in SBP 
indicating that XOR does not exert any major causal role in the development 
of hypertension. The results also provide evidence that physiological levels of 
circulating urate do not mediate the development of salt-induced hypertension 
in spontaneously hypertensive rats, since inhibition of urate producing enzyme, 
XOR, did not prevent development of hypertension. As allopurinol is known 
to inhibit also XOR catalyzed NO generation, the result indicates that XOR 
mediated nitrate recycling to NO is not involved in long-term regulation of 
blood pressure.
• Chronic XOR inhibition abolished salt-induced renal and cardiac hypertrophy, 
pointing towards a pathophysiological role of XOR in NaCl-induced target 
organ dysfunction. Allopurinol mediated alleviation of cardiac and renal 
hypertrophy occured in spite of salt-induced high systolic blood pressure.
• Nephrotoxic doses of the fungal immunosuppressive peptide, CsA, resulted 
in marked XO induction in the SHR kidney. Furthermore, CsA administration 
coupled with a high NaCl intake upregulated XO. The induction of the XO 
isoform with no effects on XDH resembles an ischemia-reperfusion setting 
described in the literature, and suggests the possibility that XO induced ROS 
production is involved in CsA induced renal damage.
• The study using Zucker fa/fa rats indicates that XOR upregulation is associated 
not only with the hypertension trait, but also with the predisposition to obesity 
and metabolic syndrome. The Zucker fa/fa strain was not salt-sensitive. In 
this model renal XOR is not regulated by Ang II. Blocking Ang II receptors 
downregulated hepatic XOR levels indicating that Ang II regulates hepatic 
purine metabolism.
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8 Conclusion
Upregulation of renal XOR is associated with the hypertensive trait. 
Furthermore, increasing NaCl intake increases renal XOR activity. In metabolic 
syndrome XOR is upregulated in the liver and in the kidney. Ang II is a 
potential regulator of hepatic XOR activity, since the angiotensin receptor 
blocker downregulated XOR. While increased NO levels did not inhibit 
XOR in vivo, decreased NO production upregulated renal XOR. The ROS 
producing XOR isoform XO, likely participates in CsA-induced nephrotoxicity 
and hypertension. XOR does not have any causal role in the development of 
hypertension. Renal and left-ventricular hypertrophy are harmful consequences 
of increased NaCl intake, which can be alleviated or even prevented in 
experimental models of hypertension by chronic administration of a specific 
XOR inhibitor.
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